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Executive Summary 
Introduction 
Health Problem 
Cardiovascular disease is a major public health issue accounting for almost 
17 million deaths per year globally. According to estimates, 40-50% of them 
are sudden cardiac deaths. Approximately 6 million sudden cardiac deaths 
are caused by ventricular tachyarrhythmias [1]. Several underlying acquired 
or congenital cardiac conditions are associated with an increased risk of ven-
tricular arrhythmias. 
Description of Technology 
The implantable cardioverter-defibrillator (ICD) device detects and termi-
nates these life-threatening ventricular tachyarrhythmias. Based on evidence 
from several trials, clinical practice guidelines of cardiological societies rec-
ommend the ICD in patients at high risk of developing ventricular tachyar-
rhythmia (primary prevention), or in patients who have experienced a prior 
episode of life-threatening ventricular tachyarrhythmias (secondary preven-
tion).  
Recently, the subcutaneous implantable ICD emerged as a promising alter-
native to the established transvenous ICD to overcome short- and long-term 
complications associated with the implantation of transvenous leads and di-
rect contact with the heart. Specifically, such complications are pneumo-
thorax, cardiac perforation, lead fracture, lead-dysfunction, infections (e.g. 
lead endocarditis) and venous thrombosis. The subcutaneous ICD leaves the 
heart and vascular system untouched. It is important to note, however, that 
the subcutaneous ICD is restricted to patient populations who are not de-
pendent on pacing therapy for bradycardia, anti-tachycardia (ATP), or resyn-
chronization (CRT).  
Based on NICE (National Institute for Health and Care Excellence) guidance 
document, the current evidence on the efficacy and safety of subcutaneous 
ICD for preventing sudden cardiac death is adequate to support the use of 
this procedure [2]. 
 
Methods 
We conducted a systematic literature review to evaluate the effectiveness and 
safety of the subcutaneous ICD compared to the conventional transvenous 
ICD in patients at an increased risk for sudden cardiac death due to an un-
derlying acquired or congenital cardiac condition. 
We searched four electronic databases: (Medline, Embase, Cochrane Library, 
CRD [Centre for reviews and dissemination]-Database).  
In addition, we searched clinical trial registries and obtained relevant litera-
ture from the manufacturer. Two authors independently conducted study se-
lection, data extraction, risk of bias assessment and rating of the quality of 
evidence using the GRADE (Grading of Recommendations Assessment, De-
velopment and Evaluation) system. 
 
sudden cardiac death: 
major public health issue  
common cause:  
ventricular 
tachyarrhythmias  
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cardiac conditions 
Implantable 
cardioverter-
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prerequisite:  
no indication for pacing 
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anti-tachycardia, or 
resynchronization 
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evidence on efficacy and 
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of the subcutaneous ICD 
Research question: 
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effectiveness and safety 
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dual study selection, 
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We synthesized evidence from identified individual studies narratively. In 
addition, we presented results from a random-effects meta-analysis from one 
systematic review [3]. Therefore, we did not perform any new meta-analysis.  
 
Results 
Available evidence 
We found seven observational studies (6,916 patients) comparing the subcu-
taneous ICD with the conventional transvenous ICD [4-10], with the largest 
study including 5,760 patients [10]. In addition, we identified one systematic 
review and meta-analysis [3] including results from five of the aforemen-
tioned observational studies (6,498 patients) [4, 6, 7, 9, 10]. 
Two reviewers assessed the risk of bias of the included observational studies 
with the Newcastle-Ottawa Scale [11]. They rated the risk of bias as high for 
three studies [4, 6, 8] and medium for four studies [5, 7, 9, 10]. The system-
atic review was medium risk of bias based on our assessment with the AM-
STAR (A MeaSurement Tool to Assess Systematic Reviews)-2 checklist [12]. 
In four studies, the control group was selected by propensity score matching 
[5, 7, 9, 10] in order to obtain similar groups. Three studies compared subcu-
taneous ICD only with a single-chamber transvenous ICD [4, 6, 8]. In four 
studies, patients in the control group received either single- or dual-chamber 
ICDs [5, 7, 9, 10]. 
Clinical effectiveness 
Three studies with 6,222 patients reported on mortality [4, 7, 10]. The dif-
ference between patients receiving subcutaneous ICDs or transvenous ICDs 
was not statistically significant regarding overall mortality in-hospital (1 study, 
5,760 patients, relative risk [RR] 2.0, 95% Confidence interval [CI]: 0.4-9.9) 
[10], mortality 6 months (1 study, 182 patients; RR 1.0; 95% CI: 0.14-6.95) [4] 
and mortality up to 5 years(1 study, 280 patients, 5-yearsurvival 96.0% vs. 
94.8%, p = 0.42) [7].  
Between patients receiving subcutaneous ICDs and transvenous ICDs, no sta-
tistical significant differences were observed regarding appropriate shocks 
during mean follow-up of 7.1 months (1 study, 138 patients, RR 0.33, 95% 
CI: 0.09-1.18) [6], 2.6 years (1 study, 138 patients, RR 0.60, 95% CI: 0.15-2.14) 
[9] and 5 years (1 study, 280 patients, hazard ratio [HR] 0.68, p = 0.36) [7]. 
Two studies with 418 patients found no statistically significant difference for 
mental quality of life assessed with 12-item Short-Form Health Survey (SF-
12) after subcutaneous and transvenous ICD implantation [5, 8]. One study 
with 84 patients [8] observed statistically significantly higher physical quality 
of life in patients with subcutaneous ICDs (mean difference [MD] 6.7, 95% 
CI: 1.88-11.52) but another study with 334 patients [5] did not (MD -0.2, 95% 
CI: -2.67-2.27).  
The quality of evidence is very low for all effectiveness outcomes. 
effectivness and safety: 
7 observations studies 
(n = 6,916 patiens) 
1 systematic review 
(n = 6,498 patients) 
risk of bias 
observational studies: 
high for 3 studies 
medium for 4 studies 
subcutaneous ICD  
vs. transvenous  
single-chamber or  
dual-chamber ICD 
effectiveness:  
7 studies 
 
 
overall mortality, 
rate of appropriate shock 
and mental quality of 
life: no statistically 
significant differences 
quality of evidence:  
very low 
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Safety 
For inappropriate shocks (4 studies, 738 patients, Odds ratio [OR] 0.87, 95% 
CI: 0.51-1.49) [3], infections (5 studies, 6,498 patients, OR 0.75, 95% CI: 0.30-
1.89) [3] and haematomas (3 studies, 6,080 patients, RR ranged from 3.00 to 
3.5) [4, 6, 10] no statistically significant differences were observed in patients 
with subcutaneous ICD compared to patients with transvenous ICD.  
However, random-effects meta-analyses showed statistically significant fewer 
lead-complications in patients with subcutaneous ICD compared to patients 
with transvenous ICD (4 studies, 6,316 patients, OR 0.13, 95% CI: 0.05-0.38) 
[3].  
The quality of evidence for safety outcomes is very low. 
Upcoming evidence 
Our searches yielded the study protocol of an investigator-initiated, multicen-
ter, randomized controlled PRAETORIAN (Prospective, RAndomizEd com-
parison of subcutaneous and tRansvenous ImplANtable cardioverter-defib-
rillator therapy) trial [13]. The planned sample size of this study is 850 pa-
tients with an indication for ICD therapy and without an indication for pac-
ing, randomized to either the subcutaneous or transvenous ICD (1:1) [14]. 
This study is powered to claim non-inferiority and/or superiority of the sub-
cutaneous ICD regarding a composite primary endpoint of inappropriate 
shocks and ICD-related complications (within 48 months). According to the 
ClinicalTrials.gov (NCT01296022) entry, the estimated completion date is 
December 2019 [14]. Thus, no results are available yet.  
 
Discussion 
The comparative evidence for the subcutaneous and transvenous ICD is 
limited to controlled observational studies with or without propensity-score 
matching and a systematic review with meta-analyses summarizing some of 
these studies. Based on this evidence, no statistically significant differences 
were observed in terms of overall mortality, rate of adequate and inadequate 
shocks, infections, and haematomas. Lead complications were statistically 
significantly less frequent in patients with subcutaneous ICDs compared to 
those with transvenous ICDs. It has to be considered that the subcutaneous 
ICD has no contact with vascular and cardiac structures. The quality of evi-
dence is very low for all outcomes.  
The available body of evidence has several limitations. 
First, the follow-up periods varied considerably among the individual stud-
ies, ranging from a few days (duration of the hospital stay) to five years after 
ICD implantation. Therefore, most of the studies did not reflect long-term 
complications. Due to the variability of follow-up periods, pooled results from 
random-effects meta-analysis are limited. 
Second, in several studies, despite matching, there were still differences of 
baseline characteristics between patients who received subcutaneous ICDs 
and patients who received conventional transvenous ICDs. In addition, not all 
studies clearly stated that they excluded patients with indications for pace-
makers, anti-tachycardia pacing, or cardiac resynchronization therapy from 
the control group with transvenous ICDs. Therefore, unevenly distributed 
prognostic factors could have influenced the outcomes.  
safety: 
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Third, for most effectiveness and safety endpoints, only few events occurred, 
limiting precision of the findings. 
The PRAETORIAN study, an adequately powered randomized controlled 
trial (RCT), will provide more reliable information of the comparative effec-
tiveness and harms of subcutaneous and transvenous ICDs. 
 
Conclusion 
Results from seven observational studies and one systematic review are in-
sufficient to conclude about the comparative effectiveness of subcutaneous 
and transvenous ICDs. These studies, however, indicate a substantially low-
er risk for lead complications in patients treated with subcutaneous ICD. 
  
inprecision: 
only few events for 
most of the endpoints 
 
results from large RCT 
are pending 
current evidence 
insufficient to conclude 
about comparative 
effectiveness, however 
substantially lower risk 
for lead complications 
with subcutaneous ICD 
Zusammenfassung 
LBI-HTA | 2018 9 
Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Herz-Kreislauferkrankungen sind ein großes Public Health Problem – sie ver-
ursachen weltweit jährlich annähernd 17 Millionen Todesfälle. Schätzungen 
zufolge gelten 40-50 % dieser Todesfälle als plötzlicher Herztod [1]. Unge-
fähr 80 % davon, also ca. 6 Millionen Todesfälle durch plötzlichen Herztod, 
sind auf eine ventrikuläre Tachyarrhythmie zurückzuführen. Verschiedenste 
zugrundeliegende angeborene oder erworbene Herzerkrankungen sind mit 
einem erhöhten Risiko für das Auftreten von ventrikulären Tachyarrhythmien 
assoziiert. 
Beschreibung der Technologie 
Der implantierbare Cardioverter-Defibrillator (ICD) erkennt und unterbricht 
diese lebensbedrohlichen Herzrhythmusstörungen. Basierend auf den Ergeb-
nissen zahlreicher Studien empfehlen kardiologische Fachgesellschaften den 
ICD bei PatientInnen mit erhöhtem Risiko für ventrikuläre Arrhythmien 
(primäre Prophylaxe) oder bei PatientInnen, die bereits eine Episode einer 
lebensbedrohlichen ventrikulären Tacharrhythmie hatten (sekundäre Prophy-
laxe).  
Als vielversprechende Alternative zum seit Jahrzenten verwendeten transve-
nösen ICD steht seit einigen Jahren der subkutane ICD zur Verfügung, um 
Kurz- und Langzeitkomplikationen einer transvenös implantierten Sonde und 
den direkten Kontakt mit dem Herzen zu vermeiden. Zu den Komplikatio-
nen, die mit der Implantation einer tranvenösen Sonde einhergehen können, 
zählen insbesondere Ventrikelperforation, Penumothorax, Sondenbrüche, Iso-
lationsdefekte der Sonden, Infektionen wie Sonden-Endokarditis und venöse 
Thrombosen. Voraussetzung für die Implantation eines subkutanen ICD ist 
jedoch, dass kein Stimulationsbedarf bei Bradykardie, kein Bedarf an anti-
tachykarder Stimulation (antitachykardes Pacing, ATP) oder keine Indikati-
on für eine Kardiale-Resynchronisationstherapie (CRT) besteht. 
Laut einem NICE (National Institute for Health and Care Excellence) Do-
kument stützt die derzeitige Evidenz zur Wirksamkeit und Sicherheit die 
Verwendung des subkutanen ICD zur Prävention des plötzlichen Herztodes 
[2]. 
 
Methoden 
Wir führten eine systematische Literaturübersicht durch. Ziel war es, die 
Wirksamkeit und Sicherheit des subkutanen ICD zur Verhinderung des plötz-
lichen Herztods mit der Wirksamkeit und Sicherheit des herkömmlichen 
transvenösen ICD zu vergleichen. 
Wir führten zur Beantwortung der Forschungsfrage eine systematische Lite-
ratursuche in vier Datenbanken durch (Medline, Embase, Cochrane Library, 
CRD [Centre for reviews and dissemination]-Database). Ergänzend durch-
suchten wir Studienregister und sendeten eine Anfrage an den Hersteller mit 
der Bitte um Zusendung relevanter Literatur.  
plötzlicher Herztod: 
Public Health Problem 
 
häufigste Ursache: 
ventrikuläre 
Tachyarrhythmie  
aufgrund angeborener 
oder erworbener 
Herzerkrankungen 
Implantierbarer 
Kardioverter-Defibrillator 
(ICD): etablierter 
konventioneller ICD mit 
transvenösen Sonden 
relativ neu: ICD mit 
subkutaner Sonde 
 
Voraussetzung: keine 
Indikation für 
Herzschrittmacher, 
antitachykarde 
Stimulation oder 
kardiale 
Resynchronisation 
NICE Guidance 
Dokument:  
derzeitige Evidenz  
zeigt Wirksamkeit  
und Sicherheit 
Forschungsfrage: 
Vergleich der 
Wirksamkeit und 
Sicherheit subkutaner 
ICD vs. transvenöser ICD 
 
systematische 
Literatursuche in  
4 Datenbanken 
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Zwei AutorenInnen führten unabhängig voneinander die Studienauswahl, die 
Datenextraktion, die Bewertung der methodischen Qualität der Studien (Bias-
Risiko) sowie der Qualität der Evidenz mit GRADE (Grading of Recommen-
dations Assessment, Development and Evaluation) durch. 
Die verfügbare Evidenz einzelner Studien fassten wir narrativ zusammen. 
Weiters beschreiben wir die Ergebnisse der Random-Effekts-Meta-Analysen 
einer systematischen Übersichtsarbeit [3]. Wir führten deshalb keine neuen 
Meta-Analysen durch.  
 
Ergebnisse 
Verfügbare Evidenz 
Wir fanden sieben Beobachtungsstudien mit 6.916 PatientInnen, die subku-
tane ICD mit herkömmlichen transvenösen ICD verglichen [4-10], wobei die 
größte Studie 5.760 PatientInnen umfasste [10]. Weiters haben wir einen sys-
tematischen Review mit Meta-Analysen identifiziert [3]. 
Zwei Autoren bewerteten das Bias-Risiko der eingeschlossenen Beobachtungs-
studien mit der Newcastle-Ottawa Scale [11]. Drei Studien [4, 6, 8] wurden 
mit hohem Bias-Risiko, vier Studien mit mittleren Bias-Risiko [5, 7, 9, 10] 
eingestuft. Den einzigen systematischen Review bewerteten wir mit niedri-
gem Bias-Risiko mittels der Checkliste AMSTAR-2 (A MeaSurement Tool to 
Assess systematic Reviews) [12]. 
In vier Studien [5, 7, 9, 10] wurde die Kontrollgruppe mittels Propensity 
Score ausgewählt, um Gruppen zu erhalten, die ein ähnliches Risiko aufwei-
sen, an einem plötzlichen Herztod zu versterben. Drei Studien verglichen den 
subkutanen ICD mit einem transvenösen Einkammer-ICD [4, 6, 8]. In vier 
weiteren Studien erhielten die PatientInnen der Kontrollgruppe sowohl Ein- 
als auch Zweikammer-ICDs [5, 7, 9, 10]. 
Klinische Wirksamkeit 
Drei Studien mit 6.222 PatientInnen berichten über Mortalität [4, 7, 10]. 
Der Unterschied zwischen PatientInnen, die einen subkutanen ICD oder ei-
nen transvenösen ICD bekommen hatten, war in Hinblick auf die Mortalität 
im Krankenhaus (1 Studie, 5.760 PatientInnen, Relatives Risiko [RR] 2,0, 95 % 
Konfidenzintervall [KI]: 0,4-9,9) [10], Mortalität nach 6 Monaten (1 Studie, 
182 PatientInnen, RR 1,0, 95 % KI: 0,14-6,95) [4] und Mortalität bis 5 Jahre 
(1 Studie, 280 PatientInnen, 5-Jahres-Überleben: 96 % vs. 94,8 %, p = 0,42) 
statistisch nicht signifikant [7]. 
Der Unterschied bei adäquaten Schocks zwischen PatientInnen, die einen 
subkutanen ICD und PatientInnen, die einen transvenösen ICD erhielten, 
war bei einer mittleren Beobachtungszeit von 7.1 Monaten (1 Studie, 138 Pa-
tientInnen, RR 0,33, 95 % KI: 0,09-1,18) [6], 2.6 Jahren (1 Studie, 138 Pati-
entInnen, RR 0,60, 95 % KI: 1,15-2,14) [9] sowie 5 Jahren (1 Studie, 280 Pa-
tientInnen, Hazard Ratio [HR] 0,68, p = 0,36) [7] statistisch nicht signifikant. 
Die mentale Lebensqualität, die mittels 12-item Short-Form Health Survery 
(SF-12) erhoben wurde, war in zwei Studien mit 418 PatientInnen nicht sta-
tistisch signifikant unterschiedlich [5, 8]. Bei der physischen Lebensqualität 
zeigte eine Studie mit 84 PatientInnen [8] einen statistisch signifikant höhe-
ren Score bei PatientInnen mit subkutanem ICD (mittlere Differenz [MD] 
6,7, 95 % KI: 1,88-11,52), eine andere Studie mit 334 PatientInnen [5] je-
doch nicht (MD -0,2, 95 % CI: -2,67-2,27).  
duale Studienauswahl, 
Datenextraktion, 
Bewertung des  
Bias-Risikos sowie der 
Qualität der Evidenz 
nach GRADE 
verfügbare Evidenz: 
Wirksamkeit und 
Sicherheit : 
7 vergleichende 
Beobachtungsstudien  
(n = 6.916 PatientInnen)  
1 Systematischer Review  
(n = 6.498 PatientInnen) 
 
Bias-Risiko der 
eingeschlossenen 
Beobachtungsstudien:  
hoch für 3 Studien  
medium für 4 Studien 
Matching mit Propensity-
Score: 4 Studien  
  
Subkutaner ICD  
vs. transvenöser Ein- 
oder Zweikammer-ICD 
Wirksamkeit:  
7 Beobachtungs-studien  
 
 
Gesamtmortalität,  
adäquate Schocks und 
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kein statistisch 
signifikanter 
Unterschied 
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Die Qualität der Evidenz für die oben genannten Endpunkte ist sehr niedrig. 
Sicherheit 
Inadäquate Schocks (4 Studien, 738 PatientInnen, Odds Ratio [OR] 0,87, 95 % 
KI: 0,51-1,49) [3], Infektionen (5 Studien [3], 6.489 PatientInnen, OR 0,75, 
95 % KI: 0,30-1,89) und Hämatome (3 Studien, 6.080 PatientInnen, RR von 
3,00 bis 3,5) [4, 6, 10] waren nicht statistisch signifikant unterschiedlich bei 
PatientInnen mit subkutanen im Vergleich zu PatientInnen mit transvenö-
sen ICD. 
Jedoch ergab eine Meta-Analyse statistisch signifikant weniger Sondenkom-
plikationen mit dem subkutanen ICD als mit dem transvenösen ICD (4 Stu-
dien, 6.316 PatientInnen, OR 0,13, 95 % KI: 0,05-0,38) [3]. 
Die Qualität der Evidenz ist sehr niedrig für alle Sicherheits-Endpunkte.  
Laufende Studien 
Bei unserer Suche haben wir das Studienprotokoll der randomisiert kontrol-
lierten Multicenter-Studie PRAETORIAN (Prospective, RAndomizEd com-
parison of subcutaneous and tRansvenous ImplANtable cardioverter-defibril-
lator therapy) gefunden [13]. Diese Studie plant 850 PatientInnen mit Indi-
kationen für einen ICD, zu einem subkutanen oder transvenösen ICD zu ran-
domisieren (1:1) [14]. Die Fallzahl wurde berechnet um Nichtunterlegenheit 
und/oder Überlegenheit des subkutanen ICD in Bezug auf einen kombinier-
ten, primären Endpunkt (inadäquater Schock oder ICD-assoziierte Kompli-
kationen innerhalb von 48 Monaten) zu zeigen. Nach dem ClinicalTrials.gov 
Eintrag (NCT01296022) wird die Studie voraussichtlich im Dezember 2019 
beendet [14]. Deshalb liegen derzeit noch keine Resultate vor. 
 
Diskussion 
Wie dieser Review zeigt, ist die Evidenz bezüglich Vergleichs des subkutanen 
mit dem transvenösen ICD auf kontrollierte Beobachtungsstudien mit oder 
ohne Propensity-Score-Matching beschränkt. Ein rezent publizierter Syste-
matischer Review mit Meta-Analysen hat die Ergebnisse einiger dieser Stu-
dien zusammengefasst und analysiert. Die vorliegende Evidenz zeigte keinen 
statistisch signifikanten Unterschied bei PatientInnen, die einen subkutanen 
ICD oder einen transvenösen Ein- oder Zweikammer-ICD erhielten in Bezug 
auf Gesamtmortalität, adäquaten und inadäquaten Schocks, Infektionen, Hä-
matome, und mentaler Lebensqualität. Sondenkomplikationen waren jedoch 
statistisch signifikant seltener bei PatientInnen, die einen subkutanen ICD 
erhalten hatten als bei PatientInnen mit transvenösem ICD. Dabei muss be-
rücksichtig werden, dass bei einem subkutanen ICD die Sonde nicht trans-
venös platziert wird und auch kein direkter Kontakt mit kardialen Struktu-
ren besteht. 
Die verfügbare Evidenz hat einige Einschränkungen. 
Der Beobachtungszeitraum unterscheidet sich deutlich zwischen den einzel-
nen Studien und reichte von der Dauer des Krankenhausaufenthaltes bis zu 
fünf Jahre nach ICD-Implantation. Deshalb könnte es sein, dass in den meis-
ten Studien Langzeitkomplikationen nicht abgebildet wurden. Außerdem 
sind aufgrund der Variabilität des Follow-Up-Zeitraumes die Ergebnisse der 
Random-Effects-Meta-Analyse nur eingeschränkt aussagekräftig. 
Sicherheit: 
5 Beobachtungsstudien:  
kein statistisch 
signifikanter Unterschied 
bei inadäquaten Schocks, 
Infektionen und 
Hämatomen; 
Sondenkomplikationen 
statistisch signifikant 
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subkutanem ICD; 
Qualität der Evidenz: 
sehr niedrig 
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Trotz Matching zeigten sich in einigen Studien teilweise bei den Baseline-
Charakteristika Unterschiede zwischen PatientInnen, die einen subkutanen 
ICD erhielten und PatientInnen, bei denen ein herkömmlicher transvenöser 
ICD implantiert wurde. Hervorzuheben ist weiters, dass nicht alle Studien 
PatientInnen in der Kontrollgruppe mit transvenösem ICD mit Indikation 
für Herzschrittmacher, antitachykarde Stimulation oder kardialer Resynchro-
nisations-Therapie ausschlossen. Deshalb könnten ungleichmäßig verteilte 
prognostische Faktoren die Ergebnisse beeinflusst haben. 
Beim Großteil der Endpunkte für Wirksamkeit und Sicherheit traten nur 
wenige Ereignisse auf, was die Präzision der Ergebnisse einschränkt.  
Die derzeit laufende randomisiert kontrollierte PRAETORIAN-Studie mit 
adäquater Power könnte verlässlichere Ergebnisse zum Vergleich des subku-
tanen ICD mit dem transvenösen ICD liefern.  
 
Empfehlung  
Die vorliegenden Ergebnisse aus sieben Beobachtungsstudien sind unzurei-
chend, um eine Aussage über die Wirksamkeit des subkutanen ICDs im Ver-
gleich zum transvenösen ICD treffen zu können. Diese Studien zeigten je-
doch statistisch signifikant weniger Sondenkomplikationen bei PatientInnen, 
die einen subkutanen ICD erhielten. 
 
Baseline-PatientInnen-
Charakteristika  
trotz Matching 
unterschiedlich in 
manchen Studien 
eingeschränkte 
Präzision aufgrund 
weniger Ergebnisse bei 
einigen Endpunkten  
Evidenz derzeit 
unzureichend für  
den Vergleich der 
Wirksamkeit, jedoch 
deutlich geringeres 
Risiko für 
Sondenkomplikationen 
mit subkutanen ICD  
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1 Scope 
1.1 PICO question 
Is the subcutaneous ICD compared to the conventional transvenous ICD 
equally or more effective and/or safer for the prevention of sudden cardiac 
death in patients at an increased risk? 
 
 
1.2 Inclusion criteria 
Table 1-1 summarizes the inclusion criteria for relevant studies. 
Table 1-1: Inclusion criteria 
Population Adults (18 years or older) with an underlying cardiac condition/disease associated with 
an increased risk of sudden cardiac death and indication for an implantable cardioverter-
defibrillator for primary or secondary prevention. 
According to the European Society of Cardiology (ESC) guideline, primary and secondary 
prevention are defined as follows [15]: 
Primary prevention of sudden cardiac death: Therapies to reduce the risk of sudden 
cardiac death in individuals who are at risk of sudden cardiac death but have not yet 
experienced an aborted cardiac arrest or life-threatening arrhythmias [15] 
Secondary prevention of sudden cardiac death: Therapies to reduce the risk of sudden 
cardiac death in patients who have already experienced an aborted cardiac arrest or  
life-threatening arrhythmias [15] 
2018 ICD-10-CM Diagnosis Code: I46.2 Cardiac arrest due to underlying cardiac condition 
MeSH terms: Death, Sudden, Cardiac (Tree Numbers: C14.280.383.220, 
C23.550.260.322.250, MeSH Unique ID: D016757) 
Intervention Subcutaneously implantable cardioverter-defibrillator (ICD) 
2018 ICD-10-CM Diagnosis Code: Z95.810 Presence of automatic (implantable)  
cardiac defibrillator 
MeSH terms: Defibrillators, Implantable (Tree Numbers: E07.305.250.159.175, 
E07.305.250.319.175, E07.695.202.175, MeSH Unique ID: D017147) 
Control Single- or dual-chamber, conventional transvenous implantable  
cardioverter-defibrillator (ICD) 
Rationale: The transvenous ICD is an established and broadly used device for  
primary and secondary prevention in patients at risk of sudden cardiac death.  
Several randomized controlled trials have demonstrated its benefit. 
Outcomes Rationale: For selection of relevant outcomes reflecting benefit and harms, we relied 
primarily on a recently-published systematic review [3]. 
Effectiveness  All-cause mortality 
 Appropriate shocks 
Safety  Inappropriate shocks 
 Lead complications 
 Infections 
 Haematoma 
 Pericardial tamponade 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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Study design  
Effectiveness  Randomized controlled trials  
 Observational studies with control group 
 Systematic reviews 
Excluded: conference abstracts, narrative reviews, letters to the editor, case reports, 
case series, retrospective and prospective single-arm studies 
Safety  Randomized controlled trials 
 Observational studies with control group 
 Systematic reviews 
Excluded: conference abstracts, narrative reviews, letters to the editor, case reports, 
retrospective and prospective single-arm studies 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is the subcutaneous ICD and the transvenous ICD? 
A0020 For which indications has the technology received marketing authorisation or CE marking? 
B0002 What is the claimed benefit of subcutaneous ICD in relation to the transvenous ICD? 
B0003 What is the phase of development and implementation of the subcutaneous ICD and the 
transvenous? 
B0004 Who administers the subcutaneous ICD and transvenous ICD and in what context and level  
of care are they provided? 
B0008 What kind of special premises are needed to use the subcutaneous ICD and transvenous ICD? 
B0009 What supplies are needed to use the subcutaneous ICD and transvenous ICD? 
A0021 What is the reimbursement status of the subcutaneous ICD? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is the subcutaneous ICD used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for the disease or health condition? 
A0004 What is the natural course of the disease or health condition? 
A0005 What is the burden of disease for the patients with the disease or health condition? 
A0006 What are the consequences of the disease or health condition for the society? 
A0024 How is the disease or health condition currently diagnosed according to published guidelines 
and in practice? 
A0025 How is the disease or health condition currently managed according to published guidelines 
and in practice? 
A0007 What is the target population for this assessment?  
A0023 How many people belong to the target population? 
A0011 How much are the technologies utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of the subcutaneous ICD on mortality? 
D0005 How does the subcutaneous ICD affect symptoms and findings (severity, frequency) of the 
disease or health condition? 
D0006 How does the technology affect progression (or recurrence) of the disease or health condition? 
D0011 What is the effect of the technology on patients’ body functions? 
D0016 How does the use of technology affect activities of daily living? 
D0012 What is the effect of the subcutaneous ICD on generic health-related quality of life? 
D0013 What is the effect of the t subcutaneous ICD on disease-specific quality of life? 
 
Subcutaneous implantable cardioverter defibrillator (ICD) 
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Safety 
Element ID Research question 
C0008 How safe is the subcutaneous ICD in comparison to the transvenous ICD? 
C0002 Are the harms related to dosage or frequency of applying the technology? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use  
of the subcutaneous ICD? 
C0007 Are the subcutaneous ICD and transvenous ICD associated with user-dependent harms? 
 
 
2.2 Sources 
Description of the technology, health problem and current use 
 Background publications identified by database search  
(see Section 2.3) and hand search 
 Clinical practice guidelines identified by hand search 
 Hand search in the POP (Planned and Ongoing Projects), AdHopHTA 
(Adopting Hospital-based Health Technology Assessment) and CRD 
(Centre for Reviews and Dissemination) databases for Health Tech-
nology Assessments 
 Documentation provided by the manufacturer 
 
 
2.3 Systematic literature search 
The systematic literature search was conducted on November 23, 2017 in the 
following databases: 
 Pubmed 
 Embase.com (Elsevier) 
 The Cochrane Library (Wiley) 
 CRD (Centre for Reviews and Dissemination) Databases: 
 DARE (Database of Abstracts of Reviews of Effects),  
 NHS-EED (National Health System-Economic Evaluation)  
Database 
 HTA (Health Technology Assessment) Database 
The systematic search was limited to the years 2000 to 2017. After dedupli-
cation, 569 citations were included overall. The specific search strategy em-
ployed can be found in the Appendix p55. 
Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trials registries (ClinicalTrials.gov; WHO-ICTRP [World Health 
Organization International Clinical Trials Registry Platform]); EU Clinical 
Trials) was conducted on November 23, 2017, resulting in 20 potential rele-
vant hits after deduplication. 
Quellen 
systematische 
Literatursuche in  
4 Datenbanken  
Suche nach  
laufenden Studien; 
Kontaktaufnahme mit 
Herstellern 
Methods 
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We screened 139 references submitted by the manufacturer of approved sub-
cutaneous ICDs (Boston Scientific).  
By hand-search, 12 additional references were found, resulting in 740 citations 
overall. 
 
 
2.4 Flow chart of study selection 
Overall, 740 citations were identified after the removal of duplicates. The re-
ferences were screened by two independent researchers (GW, AG) and, in case 
of disagreement, a third researcher was involved to resolve the differences. 
The selection process is displayed in Figure 2-1. 
 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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2.5 Analysis 
We extracted data from included studies into data extraction tables based on 
the study design and research question (see Appendix Table A-1). An inde-
pendent second reviewer (TS, EP) validated the data for accuracy.  
In addition to data from seven observational studies, we obtained data from 
the meta-analysis of one systematic review. We did not conduct any additional 
meta-analysis. We used mean quality of life scores and standard deviations 
to calculate mean differences and 95% confidence intervals. 
We calculated relative risk for binary outcomes if appropriate. 
Two researchers (GW, TS) conducted risk of bias assessments independently. 
For observational studies they used the Newcastle-Ottawa Scale [11] (see Ta-
ble A-2 ); for the systematic reviews, AMSTAR-2 (Assessing the Methodolog-
ical Quality of Systematic Reviews) [12](see Table A-3). We resolved differ-
ences by consensus.   
2.6 Synthesis 
Based on the data-extraction-table (see Appendix Table A-1), data on each 
selected outcome were synthesized. Quality of evidence was assessed across 
studies for each outcome according to GRADE (Grading of Recommenda-
tions Assessment, Development and Evaluation) [16]. The research questions 
were answered in plain text format with reference to GRADE evidence ta-
bles (see Table A-4).  
 
 
Datenextraktion  
in Tabellen 
Zusammenfassung der 
Ergebnisse einer 
Random-Effects  
Meta-Analyse eines 
rezent publizierten 
systematischen Reviews 
 
Risk of Bias Bewertung 
mit Newcastle-Ottawa 
Scale und AMSTAR-2 
Zusammenfassung  
der Ergebnisse 
 
Bewertung der Qualität 
der Evidenz mit GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is the subcutaneous and the transvenous ICD? 
The subcutaneous ICD and the transvenous ICD continuously monitor heart 
rate and deliver shock therapy in the event of life-threatening tachycardia, 
and convert the abnormal heart rhythm back to normal [17].  
Subcutaneous ICDs differ from transvenous ICDs in that the lead is placed 
subcutaneously i.e. directly under the skin rather than transvenously and is 
not directly attached to the heart [18]. The subcutaneous ICD senses cardiac 
signals, however, is not designed to provide long-term pacing [2].  
Subcutaneous ICDs consist of a pulse generator placed on the left side of the 
chest at the mid-axillary line between the fifth and sixth intercostal spaces. 
A lead with two sensing electrodes and a shocking coil, which can defibrillate 
most patients at 80 Joule, are placed subcutaneously adjacent to the sternum 
[15]. The pulse generator housing serves as an electrode for defibrillation and 
can also serve as an optional electrode for sensing.  
Patients need to undergo an ECG to assess QRS-T wave morphology prior to 
implant to check for susceptibility to under-sensing of ventricular tachycar-
dia/ventricular fibrillation and inappropriate shocks [17]. 
A drawback of the subcutaneous ICD is T-wave oversensing which can lead 
to inappropriate therapy [19]. Other potential causes of oversensing are elec-
tromagnetic interference or myopotentials.  
Other limitations are the lack of evidence regarding long-term durability/ 
longevity of subcutaneous ICD leads and experience regarding lead re-in-
terventions. 
Transvenous ICDs consist of a generator, which is usually implanted in a 
pocket in the pectoral region below the left shoulder, and a transvenous right 
ventricular lead containing the shock coils and pacing electrode. Additional 
leads may be connected to right atrial or left ventricular pacing, sensing, and 
defibrillation. The leads are inserted through an incision into a vein and 
guided to the heart under fluoroscopic guidance. The lead tip is attached to 
the heart, while the other end of the lead is attached to the pulse generator 
[17, 20] 
A0020 – For which indications has subcutaneous ICD  
received marketing authorisation or CE marking? 
The Cameron Health subcutaneous ICD system (later bought by Boston Sci-
entific) received CE-marking (CE: 623289) in 2009 for use in eligible pa-
tients for the prevention of sudden cardiac death. The second generation 
EMBLEM™ S-ICD System and EMBLEM MRI S-ICD system received CE 
marking in 2015. 
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B0002 – What is the claimed benefit of the  
subcutaneous ICD in relation to the transvenous ICD? 
Subcutaneous ICD technology enables the implantation of a defibrillator sys-
tem without transvenous ICD leads. The lead is placed subcutaneously rather 
than transvenously and is not directly attached to the heart, which avoids 
problems associated with accessing the heart via the vascular system and 
complications with the transvenous leads of the transvenous ICD system [15]. 
Specifically, such complications are pneumothorax, cardiac perforation, lead 
fracture, lead dysfunction, infections (e.g. lead endocarditis) and venous 
thrombosis. Implantation is done via primarily anatomical landmarks, min-
imizing the need for fluoroscopy [17].  
B0003 – What is the phase of development and  
implementation of the subcutaneous ICD and transvenous ICD? 
Subcutaneous ICD was introduced in human feasibility trials in 2002 and 
clinical trials in 2008. Subcutaneous ICD later received CE marking in 2009. 
Food and Drug Administration (FDA) approval was obtained in September 
2012. The second generation EMBLEM™ S-ICD system and EMBLEM™ 
MRI S-ICD system were introduced in 2015. The use of the subcutaneous 
ICD in clinical practice is constantly increasing.  
After first human implantation in 1980 [21], the transvenous ICD has been 
now in use for almost three decades and is an established and broadly used 
medical device. Several trials have demonstrated its benefit in primary or 
secondary prevention patient populations [22-24]. 
 
Administration, Investments, personnel and  
tools required to use the technology and the comparator(s) 
B0004 – Who administers the subcutaneous ICD and transvenous ICD 
and in what context and level of care are they provided? 
The subcutaneous and transvenous ICD is implanted by a cardiologist or a 
cardiac surgeon experienced in implanting these devices. 
B0008 – What kind of special premises  
are needed to use the subcutaneous and transvenous ICD? 
Both devices, the subcutaneous and transvenous ICDs, are usually implanted 
at a cardiac catheterisation laboratory or in an operating theater.  
B0009 – What supplies are needed  
to use subcutaneous ICD and transvenous ICD? 
For ICD implantation, patients are monitored by an anaesthesiologist and 
usually receive regional anaesthesia with analgosedation. The implantation 
procedure is performed under sterile conditions. The implanting physician 
is supported by specialized trained assistance/nurses. 
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status of the subcutaneous ICD? 
The subcutaneous ICD does not yet have its own settlement rate and is cur-
rently being billed as a transvenous single or dual-chamber ICD.  
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
is subcutaneous ICD used? 
Both transvenous and subcutaneous ICDs are implanted in patients at risk 
of sudden cardiac death. Ischemic heart disease is the leading structural heart 
disease, however, non-ischemic cardiomyopathy and other structural abnor-
malities, such as arrhythmogenic ventricular dysplasia and hypertrophic car-
diomyopathy, may also cause sudden cardiac death [2].  
Subcutaneous ICDs cannot achieve adequate arrhythmia sensing for all pa-
tients, and neither provide bradycardia nor anti-tachycardia pacing, which are 
both possible with the transvenous ICD [17]. Thus, patients requiring brady-
cardia pacing are not suitable candidates for subcutaneous ICDs, unless pac-
ing is only required immediately after shock delivery, as transcutaneous pac-
ing can be delivered for 30 seconds after the shock. Patients suffering from 
tachyarrhythmia that is easily resolved by anti-tachycardia pacing, and pa-
tients needing cardiac resynchronization therapy, are also not candidates for 
subcutaneous ICDs [15].  
Potential candidates for subcutaneous ICDs include paediatric patients with 
congenital heart disease, those with difficult venous access (obstruction, ve-
nous abnormality), chronic indwelling catheters, high infection risk, or young 
patients with electrical heart disease (e.g. Brugada Syndrome, long QT syn-
drome, short QT syndrome, and hypertrophic cardiomyopathy) [25]. 
A0002 – What is the disease or health condition  
in the scope of this assessment?  
Primary and secondary prevention of sudden cardiac death.  
The term sudden cardiac death is defined as [15]: 
 A congenital, or acquired, potentially fatal cardiac condition known 
to be present in life; or  
 Autopsy results showing cardiac or vascular anomaly as the probable 
cause of the event; or 
 No obvious extra-cardiac causes found during post-mortem examination 
and therefore an arrhythmic event is likely the cause of death. 
A0003 – What are the known risk factors  
for the disease or health condition? 
In younger patients, channelopathies, myocarditis, cardiomyopathies, and 
substance abuse are the predominant cardiac diseases associated with sud-
den cardiac death [15]. 
In older patients, the presence of chronic degenerative diseases, such as val-
vular heart diseases, coronary artery diseases (CAD), and heart failure (HF), 
are the main causes of sudden cardiac death [15].  
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Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for patients with the disease  
or health condition? 
Cardiovascular disease is a major public health issue accounting for almost 
17 million deaths per year globally. According to estimates, 40-50% of deaths 
are sudden cardiac deaths, with approximately 80% (6 millions) of them due 
to ventricular tachyarrhythmias [1].  
Several underlying acquired or congenital cardiac conditions are associated 
with an increased risk of ventricular arrhythmias. 
A0006 – What are the consequences of the disease  
or health condition for the society? 
In one observational study with 138 patients, the mean cost per patient in-
cluding implant and complication costs was £12,601 ± 1,786 for the subcu-
taneous ICD and £9,967 ± 4,511 for the transvenous ICD (p = 0.0001) [9]. 
 
Current clinical management of the disease or health condition 
A0024 – How is the disease or health condition currently diagnosed 
according to published guidelines and in practice? 
Clinical history, physical examination and electrocardiogram (ECG) are the 
first step in diagnostic algorithm of congenital and acquired cardiac disease. 
Echocardiography is recommended for assessment of left ventricular func-
tion and detection of structural heart disease. Coronary angiography is ap-
plied in patients with suspected coronary artery disease (CAD). 
Additional patient assessment, e.g. stress test, holter 48 hours, cardiovascu-
lar magnetic resonance imaging, drug challenges, electrophysiological study 
or genetic testing is performed according to suspected cardiac condition. 
A0025 – How is the disease or health condition currently managed 
according to published guidelines and in practice? 
In general, ICD is recommend for primary prevention of sudden cardiac death 
in certain patients with ischaemic cardiomyopathy, post myocardial infarc-
tion, non-ischaemic cardiomyopathy, inherited arrhythmia syndromes or in-
herited cardiomyopathies. In patients with history of cardiac arrest or life-
threating ventricular arrhythmia ICD is recommended for secondary preven-
tion of sudden cardiac death if certain criteria are met. Usually transvenous 
ICDs systems are implanted, however, guidelines recommend to consider the 
use of the subcutaneous ICD as follows [15]: 
 Subcutaneous ICDs should be considered as an alternative to transvenous 
ICDs in patients with an indication for an ICD when pacing therapy for 
bradycardia support, cardiac resynchronization or anti-tachycardia pacing 
is not needed. (Class IIa, Level C) 
 The subcutaneous ICD may be considered as a useful alternative to the trans-
venous ICD system when venous access is difficult, after the removal of a 
transvenous ICD for infections or in young patients with a long-term need 
for ICD therapy (Class IIa, Level C) 
The 2017 AHA/ACC/HRS Guideline for Management of Patients With Ven-
tricular Arrhythmias and the Prevention of Sudden Cardiac Death state the 
following recommendations [17]: 
sudden cardiac death: 
major public health issue 
common cause:  
ventricular 
tachyarhythmias due  
to underlying cardiac 
conditions 
Basisdiagnostik:  
Anamnese, 
Physikalische 
Krankenuntersuchung, 
EKG, Echokardiographie  
weitere Abklärung  
je nach 
Verdachtsdiagnose 
ESC Leitlinie: 
Subkutaner ICD sollte 
bei Patientinnen ohne 
Notwenigkeit für 
Schrittmacher, antitachy-
kardes Pacing oder 
Resynchronisations 
Therapie erwogen 
werden  
(Klasse IIa, Level C) 
kann bei schwierigem 
Venenzugang, nach 
Entfernung eines trans-
venösen ICDs aufgrund 
einer Infektion oder bei 
jungen PatientInnen 
erwogen werden  
(Klasse IIa, Level C 
Health Problem and Current Use 
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 In patients who meet criteria for an ICD who have inadequate vascular ac-
cess or are at high risk for infection, and in whom pacing for bradycardia or 
VT termination or as part of CRT is neither needed nor anticipated, a sub-
cutaneous implantable cardioverter-defibrillator is recommended   
(Class I, Level B) 
 In patients who meet indication for an ICD, implantation of a subcutaneous 
implantable cardioverter-defibrillator is reasonable if pacing for bradycardia 
or VT termination or as part of CRT is neither needed nor anticipated   
(Class IIa, Level B) 
Based on NICE (National Institute for Health and Care Excellence) guidance 
document, current evidence on the efficacy and safety of subcutaneous ICD 
for preventing sudden cardiac death is adequate to support the use of this 
procedure [2]. 
 
Target population 
A0007 – What is the target population in this assessment? 
Patients with congenital or acquired cardiac disease at high risk for sudden 
cardiac death.  
According to the European Society of Cardiology (ESC) guideline, primary 
and secondary prevention are defined as follows [15]: 
 Primary prevention of sudden cardiac death: Therapies to reduce the risk 
of sudden cardiac death in individuals who are at risk of sudden car-
diac death but have not yet experienced an aborted cardiac arrest or 
life-threatening arrhythmias [15] 
 Secondary prevention of sudden cardiac death: Therapies to reduce the 
risk of sudden cardiac death in patients who have already experienced 
an aborted cardiac arrest or life-threatening arrhythmias [15] 
A0023 – How many people belong to the target population?  
A0011 – How much is the subcutaneous ICD utilised? It is estimated that up to 55% of patients with an ICD indication are poten-
tial candidates for a subcutaneous device in clinical practice [26]. 
Based on the statistical report from the European Heart Rhythm Association, 
in Austria, 1,296 ICDs were implanted in the year 2013 [27]. 
In the United States, based on the National Cardiovascular Data Registry 
(ICD Registry), 393,734 ICDs were implanted between September 28, 2012 
and March 31, 2015. Among them, 3,717 (0.9%) were subcutaneous ICDs 
[10]. 
 
AHA/ACC/HRS Leitlinie 
2017 Empfehlungen: 
Klasse I, Level B 
Klasse IIa, Level B 
NICE Guidance 
Dokument:  
derzeitige Evidenz  
zeigt Wirksamkeit  
und Sicherheit des 
subkutanen ICDs 
PatientInnen mit 
angeborenere oder 
erworberener 
Herzerkrankung die  
mit einem erhöhten 
Risiko des plötzlichen 
Herztodes assoziiert sind 
Primäre oder sekundäre 
Prävention des 
plötzlichen Herztodes 
Österreich:  
2013: 1.296 ICD 
Implantationen 
 
USA:  
>390.000 ICD 
Implantationen in  
2,5 Jahren, davon 3.717 
(0,9 %) subkutane ICDs 
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 All-cause mortality 
 Appropriate shock 
Appropriate shock is usually defined as a shock delivery  
for ventricular tachycardia or ventricular fibrillation.  
 
 
5.2 Included studies 
We identified seven eligible observational studies with 6,916 patients [4-10] 
and one systematic review [3] addressing our research question. From the 
systematic review we obtained results of quantitative analysis (meta-analyses).  
Our search also identified a second systematic review, but it did not include 
recently published studies comparing the subcutaneous with the transvenous 
ICD [28]. 
Study characteristics and results of included studies are displayed in Table 
A-1 and in the evidence profile in Table A-4 
The maximum follow-up in the studies ranged from the duration of the hos-
pital stay to five years after implantation. In four studies, the control group 
was selected by propensity score matching [5, 7, 9, 10] in order to obtain 
similar groups. Three studies compared a subcutaneous ICD with a single-
chamber transvenous ICD [4, 6, 8]. In four studies, patients in the control 
group received either single- or dual-chamber ICDs [5, 7, 9, 10]. 
The largest retrospective observational study involving a total of 5,760 patients 
from the National Cardiovascular Data Registry (NCDR) ICD Registry com-
pared the effectiveness and safety of the subcutaneous ICD to the single-
chamber ICD and dual-chamber ICD for multiple clinical endpoints during 
hospitalization [10]. Propensity score matching took into account implanta-
tion date, patient characteristics, and physician characteristics.  
The other retrospective observational studies had longer observation periods 
but analyzed significantly fewer patients. 
  
eingeschlossene 
Publikationen: 
7 Beobachtungsstudien 
mit 6.916 PatientInnen 
 
1 Systematischer Review 
mit Meta-Analyse  
aus 5 dieser 
Beobachtungsstudien  
Follow-up Zeitraum der 
identifizierten Studien 
sehr variabel:  
Krankenhausaufenthalt 
bis 5 Jahre 
größte retrospektive 
Beobachtungsstudie  
mit Propensity Score 
Matching analysierte 
Daten von 5.760 
PatientInnen aus dem 
NCDR ICD Register 
Subcutaneous implantable cardioverter defibrillator (ICD) 
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5.3 Results 
Mortality 
D0001 – What is the expected beneficial effect  
of the subcutaneous ICD on mortality? 
All-cause mortality 
Three retrospective observational studies with 6,222 patients [4, 7, 10] showed 
no statistically significant differences in mortality. Two of the studies per-
formed propensity score matching [7, 10].  
In all three studies, there were no statistically significant differences in mor-
tality rates between the two groups. In the largest observational study involv-
ing a total of 5,760 patients, 0.2% (3 of 1,920) died during hospitalization in 
the subcutaneous ICD group, 0.1% (2 of 1,920; p> 0.99) in the single-chamber 
ICD group, and 0.05% (1 of 1,920, p = 0.64) in patients with dual-chamber 
ICD. No statistically significant differences were found if patients with sub-
cutaneous ICD compared to all patients with transvenous ICD (3 of 1920 vs. 
3 of 3840; relative risk [RR] 2.0, 95% confidence interval [CI]: 0.4-9.9, [self-
calculated]) [10]. 
In a smaller study with 280 participants, 5-year survival rate was 96.0% (95% 
CI: 90.1-100.0%) in the subcutaneous ICD group compared to 94.8% (95% 
CI: 90.7-99.0%) in the transvenous ICD group (p = 0.42) [7]. Patients with 
pacemaker indication were not excluded in the group of patients with con-
ventional ICD and the mean observation period of the subcutaneous and 
transvenous group was different (5 years vs. 3 years) [7]. 
 
Morbidity 
D0005 – How does the subcutaneous ICD affect symptoms and findings 
(severity, frequency) of the disease or health condition? 
Appropriate shock 
In three studies (556 patients), the rate of appropriate shocks was lower in pa-
tients with subcutaneous ICDs than in patients with conventional ICDs [6, 
7, 9]. However, this difference was not statistically significant in any of the 
three studies.  
For example, the observational study with the longest follow-up [7] showed 
that adequate shocks were less frequent in patients with subcutaneous ICDs 
than in patients with transvenous ICD (8.6% [12 of 140] versus 17.1% [24 of 
140]. At 5 year, Kaplan-Meier analysis revealed estimated rate of patients with 
appropriate shocks of 17.0% (95% CI: 6.3–26.4) in the subcutaneous group 
and 21.3% (95% CI: 12.6-27.3) in the transvenous group. The hazard ratio 
(HR) adjusted for ICD programming was 0.68 [self-calculated from HR trans-
venous vs. subcutaneous ICD], p = 0.36) [7].  
In two other observational studies [6, 9] with 276 patients, the incidence of 
adequate shock deliveries was also lower in the subcutaneous ICD group 
compared to the transvenous ICD group, but difference did not reach statis-
tical significance. 
 
 
Gesamtmortalität: 
3 Beobachtungsstudien, 
kein statistisch 
signifikanter 
Unterschied 
 
Größte Studien mit  
5.760 Patientinnen  
Krankenhausmortalität 
0,2 % vs. 0,1 %,  
p > 0,99 
Studien mit längster 
Beobachtungszeit und 
280 PatientInnen:  
5-Jahres-Überleben:  
96,0 % vs. 94,8 %,  
p = 0,42 
adäquate Schockabgabe: 
in 3 Studien numerisch 
weniger bei PatientInnen 
mit subkutanen ICD als 
mit transvenösen ICD  
Unterschiede jedoch 
statistisch nicht 
signifikant 
z. B.: eine Studie mit  
280 PatientInnen: 
Kaplan-Meier Analyse 
Adäquate Schockabgabe 
5-Jahre: 17,0 % vs. 
21,3 % HR 0.68, p = 0,36 
Clinical effectiveness 
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D0006 – How does the technology affect progression (or recurrence)  
of the disease or health condition? 
No evidence was found to answer this research question 
 
Function 
D0011 – What is the effect of the subcutaneous ICD  
on patients’ body functions? 
No evidence was found to answer this research question. 
D0016 – How does the use of the subcutaneous ICD affect activities  
of daily living? 
No evidence was found to answer this research question. 
 
Health-related quality of life 
D0012 – What is the effect of the subcutaneous ICD  
on generic health-related quality of life? 
Two observational studies with 418 patients evaluated the quality of life in 
patients with subcutaneous ICD and transvenous ICD by administration of 
the generic 12-item Short-Form Health Survey (SF-12). Physical and mental 
component summary scores of the SF-12 range on a scale from 0 (poorest pos-
sible) to 100 (best possible) [5, 8]. 
One study compared the quality of life in patients with subcutaneous ICD 
from the prospective, multicentre, observational substudy of the EFFORT-
LESS S-ICD1 registry (n = 167) with a propensity score-matched cohort with 
transvenous ICD of the single-centre MIDAS study (n = 167) [5]. Multivar-
iable model adjusted for prior selected variables and baseline differences be-
tween the two cohorts revealed no statistically significant differences at base-
line, 3 months and 6 months between patients with subcutaneous ICDs and 
transvenous ICDs [5]. 
The mean physical quality of life scores (standard deviation [SD] self-calcu-
lated from 95% CI) were similar at baseline (40.5 ± 11.8 vs. 40.8 ± 10.9), 3 
months (43.6 vs. 43.9), and 6 months (43.5 ± 12 vs. 43.7 ± 11, mean differ-
ence [self-calculated] -0.2; 95% CI: -2.67-2.27). In addition, the mean mental 
quality of life score was not statistically significantly different at baseline 
(42.4 ± 11.8 vs. 42.3 ± 11.0), 3 months (45.9 vs. 45.7) and 6 months (45.2 ± 
12.5 vs. 45.1 ± 11.6, mean difference [self-calculated] 0.15; 95% CI: -2.44-
2.74). Statistically significant improvements in physical and mental quality 
of life were observed in both groups between the time of implantation and 3 
months and between the time of implantation and 6 months, but not between 
3 and 6 months [5].  
In a second observational study, 42 patients with subcutaneous ICD were 
matched to 42 patients with single-chamber transvenous ICD and evaluated 
with respect to posttraumatic stress disorder, psychological disorders and 
quality of life [8].Quality of life was assessed after mean duration of 622 days 
after subcutaneous ICD and 942 days after transvenous implantation. The 
physical well-being score obtained by the SF-12 questionnaire was statisti-
                                                             
1 Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of 
the S-ICD 
keine Evidenz vorhanden 
keine Evidenz vorhanden 
keine Evidenz vorhanden 
Lebensqualität 
gemessen mit SF-12:  
2 Studien 
Darunter  
1 Beobachtungsstudie 
mit Propensity Score 
Matching und  
334 PatientInnen 
Physische und mentale 
Lebensqualität nach 
subkutanen und 
transvenösen ICD  
ähnlich zu Beginn, 
nach 3 und 6 Monaten 
Subcutaneous implantable cardioverter defibrillator (ICD) 
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cally significantly higher with subcutaneous than transvenous ICDs (46.6 ± 
9.9 vs. 39.9 ± 12.5, mean difference [self-calculated] 6.7; 95% CI: 1.88-11.52). 
However, the mental well-being score did not statistically significantly differ 
between groups (51.9 ± 10.4 vs. 51.8 ± 10.8, mean difference [self-calculat-
ed] 0.10; 95% CI: -4.43 − 4.63) [8]. 
D0013 – What is the effect of the subcutaneous ICD  
on disease-specific quality of life? 
No evidence was found to answer this research question. 
 
 
keine Evidenz vorhanden 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Inappropriate shocks 
 Lead complications 
 Infections 
 Haematoma 
 Pericardial tamponade 
Outcomes were selected based on a recently published systematic review [3].  
 
 
6.2 Included Studies 
Five eligible observational studies [4, 6, 7, 9, 10] and one systematic review 
[3] reported data on harms. Study characteristics were described above and 
results of included studies are displayed in Table A-1 and the quality of evi-
dence is presented in Table A-4. 
 
 
6.3 Results 
Patient safety 
C0008 – How safe is the subcutaneous ICD in comparison  
to the conventional transvenous ICD? 
Inappropriate shocks 
In four observational studies (N = 738) with a follow-up period ranging from 
six months to five years, the number of patients with inappropriate shock in 
the subcutaneous ICD group and the conventional transvenous ICD group 
were reported [4, 6, 7, 9].  
Inappropriate shock was not statistically significantly different between pa-
tients with subcutaneous and transvenous ICDs based on a random-effects 
meta-analysis with four studies [4, 6, 7, 9] and 738 patients (29 of 369 vs. 44 
of 369, OR 0.87; 95% CI: 0.51-1.49) [3].  
Causes of inappropriate shock delivery differed among groups. Subanalysis 
of three studies [6, 7, 9] showed that inappropriate therapy due to supra-
ventricular tachycardia was statistically significantly less frequent with sub-
cutaneous ICD (3 of 278 vs. 29 of 278; OR 0.12; 95% CI: 0.04-0.35).  
In contrast, statistically significant more inappropriate shocks because of 
oversensing (sensing of noise, T-wave oversensing) occurred with the subcu-
taneous ICD [3]. 
Kritische Endpunkte  
zur Sicherheit 
5 Beobachtungsstudien 
und  
1 systematischer Review 
Inadäquate 
Schockabgabe:  
4 Beobachtungsstudien 
Meta-Analyse mit  
4 Studien und  
738 PatientInnen OR 
0,87 (95 % KI: 0,51-1,49) 
Subcutaneous implantable cardioverter defibrillator (ICD) 
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Lead complications 
Four observational studies reported data on lead complications [6, 7, 9, 10]. 
Three studies showed statistically significantly fewer lead complications with 
subcutaneous ICD than with transvenous ICD [6, 7, 10]. In the study with 
the longest observation period of five years, 0.7% (1 of 140) of patients with 
subcutaneous ICD experienced lead complications, while patients with trans-
venous (single and dual-chamber) ICD experienced complications in 12.1% 
of cases (17 of 140) [7]. At 5 year, Kaplan-Meier estimates of patients with 
lead complications were 0.8% (95% CI: 0-2.2) in the subcutaneous compared 
to 11.5% (95% CI: 5.3-17.2) (p = 0.03) in the transvenous group. 
Meta-analysis of four observational studies (6,316 patients) [6, 7, 9, 10] yielded 
statistically significantly fewer lead complications in the subcutaneous ICD 
group compared to the transvenous ICD group (odds ratio [OR] 0.13, 95% 
CI: 0.05–0.38) [3]. 
Infections 
Five eligible observational studies reported data on infections. Different def-
initions of an infection were used in individual studies: infections requiring 
explantation [4], infections necessitating removal of the ICD system and/ or 
antibiotic treatment [9], infection requiring revision [6], or any infection [7, 
10].  
All five studies showed no statistically significant difference in the rate of in-
fections between patients with subcutaneous ICDs and patients with con-
ventional transvenous ICDs. In the largest observational study (N = 5,760), 
infections were rare in all three groups. During the hospital stay, which last-
ed an average of one day, 0 to 0.1% of the patients had an infection (subcu-
taneous ICD: 0.05% [1 of 1,920], transvenous single-chamber ICD: 0% [0 of 
1,920], transvenous dual-chamber ICD ICD: 0.1% [2 of 1,920]) [10]. In one 
study with a follow-up to five years, the rate of infections in both groups were 
similar (Kaplan-Meier estimates 4.1% [95% CI: 0.5-7.7] vs. 3.6% [95% CI: 0.0-
7.1], p = 0.36) [7]. 
Random-effects meta-analysis (5 studies 6,498 patients) [4, 6, 7, 9, 10] sup-
port findings of individual studies, with no statistically significant difference 
of risk for infections between the subcutaneous ICD group compared with 
the transvenous ICD group (8 of 2,269 vs. 13 vs. 4,189; OR 0.75, 95% CI: 
0.30-1.89) [3]. 
Haematoma 
Overall, haematomas were rare (subcutaneous ICD: 9 of 2,080 vs. 3 of 4,000). 
Both a larger study (N = 5,760) [10] (subcutaneous ICD vs. dual-chamber 
transvenous ICD: RR 3.5, 95% CI: 0.7-19.8) and two smaller retrospective 
observational studies (N = 320) [4, 6] found no statistically significant differ-
ence between subcutaneous ICDs and transvenous single- or dual-chamber 
ICDs. 
Sonden-Komplikationen:  
4 Beobachtungsstudien 
mit 6.316 PatientInnen 
 
Meta-Analyse  
mit 4 Studien:  
statistisch signifikant 
weniger Sonden-
komplikationenmit 
subkutanem ICD  
OR 0,13 (95 % KI:  
0,05-0,38) 
Infektionen:  
5 Beobachtungsstudien 
mit insgesamt  
6.498 PatientInnen  
Meta-Analyse  
mit 5 Studien:  
kein statistisch 
signifikanter 
Unterschied OR 0,75  
(95 % KI: 0,30-1,89) 
Hämatome:  
3 Studien  
selten in beiden 
Gruppen 
Safety 
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Pericardial tamponade 
Two studies (N = 5,898) reported the rate of pericardial tamponade [9, 10]. 
In the largest study involving 5,760 patients, no pericardial tamponades oc-
curred during hospital stay in the group with subcutaneous ICDs and the 
single-chamber ICD group. However, in the dual-chamber ICD group, five 
pericardial tamponades were observed [10].  
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No evidence was found to answer this research question 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of the subcutaneous ICD? 
No evidence was found to answer this research question 
C0007 – Are the subcutaneous ICD and transvenous ICD associated  
with user-dependent harms? 
No evidence was found to answer this research question 
 
 
 
Größte Studie: 
Implantation des 
subkutanen und 
transvenösen 
Einkammer-ICD keine 
Perikardtamponade,  
5 bei Implantation eines 
Zweikammer-ICD  
keine Evidenz  
zu den Endpunkten 
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PatientInnengruppen  
und anwenderabhängige 
Schäden vorhanden 
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7 Quality of evidence 
The quality of evidence was rated according to the GRADE (Grading of Re-
commendations Assessment, Development and Evaluation) scheme [16] for 
each endpoint individually. Each study was rated by two independent re-
searchers. In case of disagreement, a third researcher was involved to resolve 
the difference. A more detailed list of criteria applied can be found in the re-
commendations of the GRADE Working Group [16]. 
GRADE uses four categories to rank the quality of evidence: 
 High = We are very confident that the true effect lies close to that of 
the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in the summary of findings table below and in the evidence profile 
in Appendix Table A-4. 
The quality of evidence for the effectiveness and safety of subcutaneous ICD 
in comparison to transvenous ICD is very low for all outcomes. 
Risk of Bias of included observational studies was assessed with the Newcas-
tle-Ottawa Scale [11] and is presented in Table A-2 in the Appendix. Three 
studies were considered as high [4, 6, 8] and four as medium risk of bias [5, 
7, 9, 10]. Main reasons for downgrading refer to selection of control group, 
comparability of cohorts and follow-up duration. 
The only systematic review was rated as medium risk of bias, since assessment 
with the AMSTAR-2 checklist [12] revealed moderate overall confidence in 
the results of the review (see Table A-3). 
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Table 7-1: Summary of findings table of subcutaneous ICD compared with transvenous ICD in patients at high risk of sudden cardiac death 
Outcomes 
Anticipated absolute effects* (95% CI) 
Relative effect 
(95% CI) 
№ of participants  
(studies) 
Certainty of  
the evidence 
(GRADE) 
Comments Risk with 
transvenous ICD 
Risk with subcutaneous ICD 
Mortality (In-hospital) [10]  
1 per 1.000 
2 per 1.000 
(0 to 8) 
RR 2.0 
(0.4 to 9.9) 
5760 
(1 observational study) 
⨁◯◯◯ 
VERY LOW a 
 
Mortality (up to 6 months) [4]  
22 per 1.000 
22 per 1.000 
(3 to 153) 
RR 1.00 
(0.14 to 6.95) 
182 
(1 observational study) 
⨁◯◯◯ 
VERY LOW b,c,d 
 
Mortality (up to 5 years) [7]  
43 per 1.000 
0 per 1.000 
(0 to 0) 
not estimable 280 
(1 observational study) 
⨁◯◯◯ 
VERY LOW c,d 
 
Appropriate shock/therapy  
(7.1 months) [6]  
130 per 1.000 
43 per 1.000 
(12 to 154) 
RR 0.33 
(0.09 to 1.18) 
138 
(1 observational study) 
⨁◯◯◯ 
VERY LOW b,c,d 
 
Appropriate shock/therapy  
(2.6 years) [9]  
72 per 1.000 
43 per 1.000 
(11 to 155) 
RR 0.60 
(0.15 to 2.14) 
138 
(1 observational study) 
⨁◯◯◯ 
VERY LOW c,d 
 
Appropriate shock/therapy  
(up to 5 years) [7]  
171 per 1.000 
120 per 1.000 
(0 to 0) 
HR 0.68 
 
280 
(1 observational study) 
⨁◯◯◯ 
VERY LOW d 
 
Inappropriate shocks [3] pooled Data of  
[4, 6, 7, 9]  
95 per 1.000 
83 per 1.000 
(51 to 135) 
OR 0.87 
(0.51 to 1.49) 
738 
(4 observational studies) 
⨁◯◯◯ 
VERY LOW a,b 
 
Lead complications [3]  
pooled Data of [6, 7, 9, 10]  
10 per 1.000 
1 per 1.000 
(1 to 4) 
OR 0.13 
(0.05 to 0.38) 
6316 
(4 observational studies) 
⨁◯◯◯ 
VERY LOW e 
 
Infections [3] pooled Data of [4, 6, 7, 9, 10]  
3 per 1.000 
2 per 1.000 
(1 to 6) 
OR 0.75 
(0.30 to 1.89) 
6498 
(5 observational studies) 
⨁◯◯◯ 
VERY LOW b 
 
Pericardial tamponade [9, 10]  
2 per 1.000 
0 per 1.000 
(0 to 1) 
RR ranged from  
0.18 to 0.33 
5898 
(2 observational studies) 
⨁◯◯◯ 
VERY LOW c 
 
Haematoma [4, 6, 10]  
1 per 1.000 
0 per 1.000 
(2 to 3) 
RR ranged from  
3.0 to 3.5 
6080 
(3 observational studies) 
⨁◯◯◯ 
VERY LOW b,c 
 
Quality of life – physical well-being score [8] 
assessed with: 12-item Short-Form Health 
Survey (SF-12)  
 The mean quality of life – physical well-
being score [8] in the intervention group 
was 6.7 higher (1.88 higher to 11.52 higher) 
- 84 
(1 observational study) 
⨁◯◯◯ 
VERY LOW b,d 
 
Quality of life – physical well-being score [5] 
assessed with: 12-item Short-Form Health 
Survey (SF-12)  
 The mean quality of life – physical well-
being score [5] in the intervention group 
was 0.2 lower (2.67 lower to 2.27 higher) 
- 334 
(1 observational study) 
⨁◯◯◯ 
VERY LOW d 
 
Quality of life – mental well-being score [8] 
assessed with: 12-item Short-Form Health 
Survey (SF-12)  
 The mean quality of life – mental well-
being score [8] in the intervention group 
was 0.1 higher (4.43 lower to 4.63 higher) 
- 84 
(1 observational study) 
⨁◯◯◯ 
VERY LOW b,d 
 
Quality of life – mental well-being score [5] 
assessed with: 12-item Short-Form Health 
Survey (SF-12)  
 The mean quality of life – mental well-
being score [5] in the intervention group 
was 0.15 higher (2.44 lower to 2.74 higher) 
- 334 
(1 observational study) 
⨁◯◯◯ 
VERY LOW d,f 
 
Explanations: *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  
Abbreviations: CI = Confidence interval; RR = Risk ratio; HR = Hazard Ratio; OR = Odds ratio; MD = Mean difference 
a Effect estimates includes appreciable benefit and harms  
b Two studies with high risk of bias [4, 6]  
c Small number of events  
d Sample size does not meet optimal information size.  
e Studies with high or medium risk of bias  
f Medium risk of bias 
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8 Discussion 
Based on the available evidence of seven observational studies [4-10] and one 
systematic review [3], comparing patients receiving subcutaneous ICDs or 
transvenous ICDs, no statistically significant differences were observed in 
terms of overall mortality, rate of adequate and inadequate shocks, infections, 
and haematomas. Some of these results, however, have wide confidence inter-
vals and encompass differences that would be clinically relevant. 
Lead complications were statistically significantly less frequent in patients 
with subcutaneous ICDs as compared to transvenous ICDs. Difference re-
garding lead complications, however, are expected by the nature of these de-
vices, as subcutaneous ICDs have no contact with cardiac structures due to 
the absence of transvenous lead implantation. 
The quality of evidence of all outcomes is very low due to risk of bias and 
imprecision, indicating substantial uncertainty about these findings.  
When interpreting the results of our evidence summary, several limitations 
related to risk of bias and to study design have to be considered: 
First, the follow-up period varied considerably among individual studies rang-
ing from the duration of the hospital stay to five years after ICD implanta-
tion. Therefore, most of the studies do not reflect long-term complications. 
Due to this limitation, pooled results from random-effects meta-analysis are 
limited.  
Second, in few studies, despite matching, there were still differences of base-
line characterises between patients who received subcutaneous ICDs and pa-
tients who had a conventional transvenous ICDs implanted. In particular, dif-
ferences in patient characteristics may have influenced outcomes. It should 
be emphasized that not all studies clearly stated that they excluded patients 
with an indication for a pacemaker, anti-tachycardia pacing or cardiac resyn-
chronization therapy from the control group with transvenous ICD. There-
fore, unevenly distributed prognostic factors could have influenced the out-
comes.  
Third, due to the small sample size (ranging from 138 to 334 patients), power 
of most of the studies is low to detect differences. However, this was over-
come by the meta-analysis of the included systematic review. 
Finally, the most important limitation is that for most effectiveness and safe-
ty endpoints, only few events occurred, limiting precision of the findings. 
Most of the non-significant results are generally indeterminate. The confi-
dence intervals are wide and include important differences. 
Applicability of included studies is summarized in Table A-5. 
Our review focused on comparative effectiveness and safety of the subcuta-
neous and transvenous ICD. For that reason, findings of two large cohort 
studies without control group, the IDE (Investigational Device Exemption) 
study [29, 30] and the EFFORTLESS (Evaluation oF FactORs ImpacTing 
CLinical Outcome and Cost EffectiveneSS of the S-ICD) study [30, 31] are 
not included in this review.  
Resultate für 
Wirksamkeit: nicht 
signifikater Unterschied  
Resultate für  
Sicherheit: weniger 
Sondenkomplikationen 
bei subkutanem ICD 
Qualität der Evidenz: 
sehr niedrig 
Bias Risiko und andere 
Limitationen 
unterschiedliche 
Beobachtungszeiträume 
der Studien von 
Krankenhausaufenthalt 
bis zu 5 Jahren 
 
trotz Matching Baseline 
Patientencharakteristika 
unterschiedlich in 
manchen Studien 
bei einigen Endpunkten 
nur wenige Ereignisse  
 breite KI die 
relevante Unterschiede 
einschließen können 
Subcutaneous implantable cardioverter defibrillator (ICD) 
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Our searches yielded the study protocol of an investigator-initiated, multi-
centre, randomized controlled PRAETORIAN (Prospective, RAndomizEd 
comparison of subcutaneous and tRansvenous ImplANtable cardioverter-de-
fibrillator therapy) trial [13]. Planned sample size of this study is 850 patients 
with an indication for ICD therapy and without an indication for pacing, 
randomized to either the subcutaneous or transvenous ICD (1:1) [14]. This 
study is adequately powered to claim non-inferiority and/or superiority of the 
subcutaneous ICD regarding a composite primary endpoint of inappropriate 
shocks and ICD-related complications (within 48 months). According to the 
ClinicalTrials.gov (NCT01296022) entry, estimated completion date is De-
cember 2019 [14]. Thus, no results are available yet. 
In addition, we found the ongoing randomized controlled ATLAS (Avoid 
Transvenous Leads in Appropriate Subjects) S-ICD trial (ClinicalTrials.gov, 
NCT02881255). Details of this trial are provided in Table A-6. 
 
Conclusion 
The results from seven observational studies and one systematic review are 
inadequate to draw conclusions about the comparative effectiveness of sub-
cutaneous and transvenous ICDs.  
These studies, however, indicate substantially lower risk for lead complica-
tions in patients with subcutaneous ICD. 
The ongoing randomized controlled PRAETORIAN study will provide more 
reliable results to answer this question. 
 
 
 
laufender RCT  
PRAETORIAN trial 
 
Subkutaner vs.  
Transvenöser ICD  
geplante Anzahl an 
Studienteilnehmern:  
850 Patienten 
 
Voraussichtliches Ende:  
Dezember 2019 
Evidenz derzeit 
unzureichend für  
den Vergleich der 
Wirksamkeit, jedoch 
deutlich geringeres 
Risiko für 
Sondenkomplikationen 
mit subkutanem ICD  
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
X The inclusion in the catalogue of benefits is recommended with restrictions. 
 The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to determine whether the subcutaneous 
ICD is equally or more effective than the transvenous ICD. Based on the 
available evidence no statistically significant differences were observed in 
terms of overall mortality, rate of adequate and inadequate shocks, infections, 
and haematomas. However, lead complications were statistically significant-
ly less frequent in patients with subcutaneous ICDs as compared to trans-
venous ICDs. Thus, inclusion in the benefit catalogue is recommended with 
restrictions.  
New study results will potentially influence the effect estimate considerably. 
The re-evaluation is recommended in year 2020 when results of an ongoing 
randomized controlled trial are published. 
 
Resultate für  
Sicherheit: weniger 
Sondenkomplikationen 
bei subkutanem ICD; 
Resultate für 
Wirksamkeit: kein 
statistisch signifikanter 
Unterschied 
Ergebnisse eines RCTs 
werden erwartet 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: Subcutaneous versus transvenous ICD: Results from observational studies 
Author, year Köbe, 2013 [6] Brouwer, 2016 [7] Friedmann, 2016 [10] Pedersen, 2016 [5] Köbe, 2017 [8] Honoarbakhsh, 2017 [9] Mithani, 2017 [4] 
Country Germany Netherlands Unites States of America Czech Republic, 
Denmark, Germany, 
Italy, the Netherlands, 
New Zealand, Portugal, 
and the United Kingdom 
Germany England Unites States of 
America 
Sponsor - - Supported by the 
American College of 
Cardiology’s National 
Cardiovascular Data 
Registry (NCDR) 
Cameron Health Inc. - - - 
Intervention Subcutaneous ICD Subcutaneous ICD Subcutaneous ICD Subcutaneous ICD Subcutaneous ICD Subcutaneous ICD Subcutaneous ICS 
Comparator Single-chamber 
transvenous ICD 
Single-chamber  
and dual-chamber 
transvenous ICD 
Single-chamber  
and dual chamber 
transvenous ICD 
Single-chamber  
and dual-chamber 
transvenous ICD 
Single-chamber 
transvenous ICD 
Single- and  
dual-chamber 
transvenous ICD 
Single-chamber 
transvenous ICD 
Study design Observational 
study Control 
matched by sex 
and age (±5 years) 
Observational 
study with 
propensity score 
matching 
Observational study 
with propensity score 
matching 
Observational study  
with propensity  
score matching 
Observational study 
Control matched by 
sex and age (±5 years) 
Retrospective 
observational study 
with propensity score 
matching 
Observational study 
Control matched 
by age, sex and 
dialysis status 
Number of 
patients, total 
and intervention 
vs. comparator 
138 
69 vs. 69 
280 
140 vs. 140 
5760 
1920 vs. 1920 vs. 1920 
334 
167 vs. 167 
84 
42 vs. 42 
138 
69 vs. 69 
182 
91 vs. 91 
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Author, year Köbe, 2013 [6] Brouwer, 2016 [7] Friedmann, 2016 [10] Pedersen, 2016 [5] Köbe, 2017 [8] Honoarbakhsh, 2017 [9] Mithani, 2017 [4] 
Inclusion  
criteria 
Indication for ICD 
implantation 
according to 
ACA/AHA and ESC 
guidelines for 
primary and 
secondary 
prevention,  
no indication for 
stimulation or 
slow ventricular 
tachycardias (VTs). 
Implantation at 
the University 
Hospitals of 
Düsseldorf, 
Munich and 
Münster, Germany 
Patients implanted 
with single- and 
dual-chamber TV-
ICDs between 
2005 and 2014 at 
the Leiden 
University Medical 
Center (LUMC), 
and patients 
implanted with  
S-ICDs between 
2009 and 2015 at 
the Academic 
Medical Center 
(AMC) 
All Patients admitted  
for ICD implantation 
(September 28,  
2012-March 31, 2015)  
and eligible for an S-ICD, 
SC TV-ICD or DC TV-ICD 
Patients implanted with  
a first generation S-ICD 
system due to a primary 
or secondary prevention 
indication according to 
local clinical guidelines 
The intervention cohort 
(EFFORTLES S-ICD QoL 
substudy) included 
prospective and first time 
implant patients from  
29 sites (Czech Republic, 
Denmark, Germany, Italy, 
Netherlands, New Zealand, 
Portugal, United Kingdom) 
from March 2011 to July 
2014. Comparison cohort 
were patients from the 
MIDAS study recruited at 
the Erasmus Medical 
Center in Rotterdam, 
Netherlands from August 
2003 to February 2010. 
Consecutive patients 
with subcutaneous 
ICD implantation and 
patients with trans-
venous single-chamber 
ICD implantation from 
hospital database, 
capable of responding 
to standardized 
questionnaire, 
previously implanted 
at Department of 
Cardiology and 
Angiology, University 
Hospital München, 
Germany and attended 
the outpatient clinic 
regularly for device 
follow-up. 
Indication for ICD 
implantation for 
primary and 
secondary prevention. 
Patients implanted 
with subcutaneous 
ICD between 2010 
and 2015 in a single 
tertiary centre, 
patients implanted a 
transvenous ICD over 
a contemporary time 
in the same centre 
(Barts Heart Center, 
London) 
All patients who 
had a subcutaneous 
ICDs implanted 
between October 22, 
2012 and September 
22, 2015 at the 
Cooper University 
Hospital, Camden, 
USA. Ninety-one 
patients who 
received 
subcutaneous ICD 
were consecutively 
identified and they 
were then matched 
to single.chamber 
transvenous ICD 
patients during this 
time frame. 
Exclusion criteria NR Patients included  
in the 
PRAETORIAN trial 
Patients with previous 
ICD, bradycardia or 
resynchronization 
indication for permanent 
pacing Patients under-
going ICD implantation 
during an acute 
hospitalization 
Patients participating in 
another study that was 
considered to interfere 
with interpretation of the 
results from the EFFORT-
LESS S-ICD Registry, had 
previously been implanted 
with an ICD, experienced 
incessant VT and/or 
spontaneously, frequently 
recurring VT, or if they 
had a bradycardia 
indication or cardiac 
resynchronization therapy 
NR Patients who had a 
concomitant pacing 
indication, 
biventricular devices, 
documentation of 
sustained mono-
morphic ventricular 
tachycardia (VT) 
likely to require anti-
tachycardia pacing 
(ATP), and advisory 
transvenous leads 
Dual-chamber 
transvenous ICD, 
Cardiac 
resynchronization 
therapy (CRT) 
Age of patients, 
yrs  
Mean ± SD: 
45.7 ± 15.7 vs.  
47.7 ± 14.7, 
p = 0.433 
Median (inter-
quartile range): 
41 (26-52) vs.  
42 (32-50), p = 0.33 
Mean ± SD: 
54.0 (15.1) vs. 53.7 (15.2) 
vs. 54.1 (15.0),  
p = NR 
Mean ± SD: 
54 ± 16 vs. 55 ± 13, 
p = 0.8831 
Mean ± SD: 
44.6 ± 12.5 vs.  
44.7 ± 12.1, 
P = 0.96 
Mean ± SD: 
35 ± 13 vs. 40 ± 10, 
p = 0.17 
Mean ± SD: 
54.93 ± 13.61 vs 
56.30 ± 12.71,  
p = 0.017 
Female n (%) 19 (27.5) vs. 
 19 (27.5), p = 1.0 
56 (40) vs. 53 (38), 
p = 0.71 
627 (32.7) vs. 598 (31.2) 
vs. 633 (33), p = NR 
45 (27%) vs 47 (28%) 
p = 0.8065 
12 (28.6) vs. 12 (28.6), 
p = 1.0 
17 (25) vs. 17 (25), 
p = 1.00 
40 (44) vs. 41 (55) 
P = 1.0 
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Author, year Köbe, 2013 [6] Brouwer, 2016 [7] Friedmann, 2016 [10] Pedersen, 2016 [5] Köbe, 2017 [8] Honoarbakhsh, 2017 [9] Mithani, 2017 [4] 
Primary 
prevention n (%) 
41 (59.4) vs.  
34 (50.0), p = 0.268 
93 (66) vs. 86 (61),  
p = 0.38 
NR 123 (74) vs. 115 (69), 
p = 0.3334 
26 (61.9) vs.  
23 (54.8), p = 0.66 
56 (81) vs. 56 (81), 
p = 1.0 
74 (81.3) vs.  
70 (76.9), p = 0.585 
First ICD 
implantation n (%) 
53 (76.8) vs. NR,  
p = NR 
121 (86) vs.  
125 (89), p = 0.47 
1920 (100) vs. 1920 
(100) vs. 1920 (100) 
167 (100) vs. 167 (100) NR NR NR 
LVEF, % Mean ± SD: 
46.2 ± 15.6 vs. 
40.6 ± 15.9,  
p = 0.084 
Median: 
50 vs. 49 
p = 0.91 
Mean ± SD: 
31.2 ± 13.7 vs. 31.4 ± 13.8 
vs. 31.2 ± 13.9, 
p = NR 
NR Mean ± SD: 
49.0 ± 13.7 vs. 
44.8 ±16.6 
p = 0.28 
Mean ± SD: 
57 ± 15 vs. 58 ±13, 
p = 0.80 
Mean ± SD 
26.79 ± 12.08 vs. 
27.78 ± 11.66,  
p = 0.534 
Atrial fibrillation or 
Atrial flutter n (%) 
NR 13 (9) vs. 21 (15),  
p = 0.14 
322 (16.8) vs. 323 (16.8) 
vs. 370 (19.3), p = NR 
36 (22) vs. 30 (18), 
p = 0.4097 
NR NR 14 (15.4) vs. 15 (16.5), 
p = 1.00 
Ischemic heart 
disease or 
Coronary artery 
disease n (%) 
11 (15.9) vs. 13 
(18.8), 
p = 0.653 
NR 879 (45.8) vs. 890 
(46.4) vs. 857 (44.6), 
p = NR 
NR 3 (7.1) vs. 6 (14.3) 
p = 0.48 
NR NR 
Ischemic cardio-
myopathy n (%) 
NR 26 (19) vs. 41 (29),  
p = NR 
NR 12 (7) vs. 12 (7),  
p = 1.00 
NR 6 (9) vs. 5 (7),  
p = 1.0 
NR 
Nonischemic 
cardiomyopathy 
n (%) 
NR 28 (20) vs. 30 (21), 
p = NR 
846 (44.1) vs. 832 (43.3) 
vs. 845 (44), P = NR 
NR NR NR 57 (62.6) vs. 51 
(56), p = 0.451 
Dilated cardio-
myopathy n (%) 
25 (36.2) vs.  
32 (46.4), p = 0.226 
NR 846 (44.1) vs. 832 (43.3) 
vs. 845 (44), p = NR 
25 (15) vs. 39 (23),  
p = 0.0516 
7 (16.7) vs. 12 (28.6), 
p = 0.30 
4 (6) vs. 5 (7), 
p = 1.0 
NR 
Hyperthrophic 
cardiomyopathy 
n (%) 
10 (14.5) vs. 4 (5.8), 
p = 0.091 
NR 123 (6.4) vs. 122 (6.4) vs. 
120 (6.3), p = NR 
22 (13) vs. 18 (11),  
p = 0.5002 
10 (23.8) vs. 3 (7.1), 
p = 0.07 
41 (59) vs. 42 (61), 
p = 1.0 
NR 
Congenital heart 
disease n (%) 
3 (4.4) vs. 3 (4.4), 
p = 1.0 
5 (4) vs. 12 (9),  
p = NR 
Ebstein anomaly: 
3 (0.2) vs. 1 (0.1) vs. 1 (0.1) 
Transposition of the  
great vessels: 
(0.2) vs. 2 (0.1) vs. 1 (0.1) 
Tetralogy of Fallot 
6 (0.3) vs. 5 (0.3) vs. 9 (0.5) 
Arrhythmogenic right 
ventricular dysplasia: 
11 (0.6) vs. 11 (0.6) vs. 
6 (0.3) 
Common ventricle: 
2 (0.1) vs. 0 vs. 0 
NR 4 (9.5) vs. 5 (11.9), 
p = 1.0 
1 (1) vs. 1(1), 
p = 1.0 
NR 
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Author, year Köbe, 2013 [6] Brouwer, 2016 [7] Friedmann, 2016 [10] Pedersen, 2016 [5] Köbe, 2017 [8] Honoarbakhsh, 2017 [9] Mithani, 2017 [4] 
Electrical heart 
disease  
or 
Syndromes 
associated with 
sudden cardiac 
death 
or 
Genetic 
arrhythmia 
syndrome 
n (%) 
Electrical heart 
disease: 
14 (20.3) vs. 2 (2.9), 
p = 0.002 
Genetic 
arrhythmia 
syndrome: 
75 (54) vs. 54 (39), 
p = NR 
Syndromes associated with 
sudden cardiac death: 
Long QT syndrome: 
66 (3.4) vs. 41 (2.1) vs.  
77 (4) 
Short QT syndrome: 
1 (0.1) vs. 0 vs. 1 (0.1)  
Brugada syndrome: 
21 (1.1) vs. 28 (1.5) vs.  
6 (0.3) Catecholeminergic 
polymorphic VT: 
1 (0.1) vs. 3 (0.2) vs. 3 (0.2) 
Idiopathic VF: 
17 (0.9) vs. 14 (0.7) vs.  
18 (0.9) 
NR Electrical heart 
disease: 
7 (16.7) vs. 2 (4.8), 
p = 0.16 
Arrhythmogenic  
right ventricular 
cardiomyopathy: 
7 (10) vs. 6 (9),  
p = 0.79 
Idiopathic ventricular 
fibrillation: 
6 (9) vs. 6 (9), p = 1.0 
Brugada Syndrome: 
4 (6) vs. 4 (6), p = 1.0 
NR 
Follow-up 
(months) 
Mean ± SD: 
7.1 ± 4.5 months 
Max: 
24 months 
Median: 
36 vs. 60 months, 
p < 0.001 
Max: 
50 months 
Max: 
In-hospital 
Max: 
6 months 
Time since ICD 
implantation 
Mean ± SD: 
Subcutaneous ICD: 
20.7 ± 10.6 months 
Single-chamber ICD: 
31.4 ± 10.4 7 months 
Mean ± SD: 
Subcutaneous ICD: 
31 ±19 months 
Transvenous ICD: 
32± 21 months 
Max: 
60 months 
Max: 
6 months 
Loss to follow-up, 
n (%) 
1 (1.4) NR 0 0 NR - - 
Outcome 
Effectiveness 
All-cause 
mortality n (%) 
Mean 7.1 months: 
Subcutaneous ICD: 
1/69 (1.4) vs. 
Single-chamber 
ICD: 1/69 (1.4), 
p = NR 
5 years: 
Subcutaneous ICD: 
2/140 (1.4) vs. 
Single/dual-chamber 
ICD: 6/140/4.6) 
Kaplan-Meier 
analysis for survival: 
96% vs. 94,8%,  
p = 0.42 
In-Hospital: 
Subcutaneous ICD: 
3/1920 (0.2) vs. Single-
chamber ICD: 2/1920 (0.1) 
p > 0.99 
Subcutaneous ICD: 
3/1920 (0.2) vs.  
Dual-chamber ICD: 
1/1920 (0.05), p = 0.64 
NR NR Mean 2.6 years: 
Subctanous ICD:  
0/69 (0) vs.  
Single-/dual-chamber 
ICD: 0/69 (0) 
6 months: 
Subcutaneous ICD: 
2/91 (2.2) vs. 
Single-chamber 
ICD: 2/91 (2.2) 
p = NR 
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Author, year Köbe, 2013 [6] Brouwer, 2016 [7] Friedmann, 2016 [10] Pedersen, 2016 [5] Köbe, 2017 [8] Honoarbakhsh, 2017 [9] Mithani, 2017 [4] 
Appropriate 
shocks n (%) 
Mean 7.1. months: 
Subcutaneous ICD: 
3/69 (4.3) vs. 
Single-chamber 
ICD: 9/69 (13.0), 
p = 0.05 
5 years: 
Subcutaneous ICD: 
12/140 (8.6) vs. 
Single/dual-chamber 
ICD: 24/140 (17.2) 
Kaplan-Meier 
analysis: 
17,0% (95% CI:  
6.3–26.4) vs.21,3% 
(95% CI: 12.6–27.3) 
Single/dual-chamber 
ICD: HR with 
adjustment for ICD 
programming: 
1.46; p = 0,36 
NR NR Subcutaneous ICD: 
1/42 (2.4) vs.  
Single-chamber ICD:  
7/42 (16.7) 
p = 0.06 
Mean 2.6 years: 
Subcutaneous ICD: 
3/69 (4.3) vs. Single-/ 
dual-chamber ICD: 
5/69 (7.2),  
p = NR 
6 months: 
Subcutaneous ICD: 
1/91 (1,1) vs. Single-
chamber ICD:  
0/91 (0),  
p = NR 
Quality of life NR NR NR 12-Item Short-Form 
Health Survey (SF-12) 
0 = poorest possible,  
100 = best possible 
Physical QoL:a 
Mean (95% CI): 
Baseline: 40.48  
(38.69-42.27) vs. 40.77 
(39.12-42.42), p = 0.8157 
3 months: 43.56  
(41.79-45.34) vs. 43.85 
(42.22-45.48), p = 0.8157 
6 months: 43.45  
(41.63-45.26) vs. 43.74 
(42.06-45.41), p = 0.8157 
Mental QoL: a 
Mean (95% CI): 
Baseline: 42.39  
(40.60-44.19) vs. 42.25 
(40.59-43.92), p = 0.9080 
3 months: 45.86  
(44.04-47.68) vs. 45.72 
(44.04-47.40), p = 0.9080 
6 months: 45.19  
(43.29-47.09) vs. 45.05 
(43.28-46.81), p = 0.9080 
12-Item Short-Form 
Health Survey(SF-12) 
0 = poorest possible 
100 = best possible 
Physical QoL: 
Mean ± SD: 
Baseline: NR 
Follow-up: 46.6 ± 9.9 
vs. 39.9 ± 12.5,  
p = 0.01 
Mental QoL: 
Mean ± SD: 
Baseline: NR 
Follow-up: 51.9 ± 10.4 
vs. 51.8 ± 10.8, 
p = 0.95 
NR NR 
  
Su
b
cu
tan
eo
u
s im
p
lan
tab
le card
io
verter d
efib
rillato
r (IC
D
) 
4
8
 
LB
I-H
T
A
| 20
18
 
Author, year Köbe, 2013 [6] Brouwer, 2016 [7] Friedmann, 2016 [10] Pedersen, 2016 [5] Köbe, 2017 [8] Honoarbakhsh, 2017 [9] Mithani, 2017 [4] 
Safety 
Inappropriate 
shocks  
n (%) 
Mean 7.1. months: 
Subcutaneous ICD: 
5/69 (7.2) vs. 
Single chamber 
ICD: 3/69 (4.3) 
p = NR 
5 years: 
Subcutaneous ICD: 
20/140 (14.3) vs. 
Single/dual-chamber 
ICD: 22/140 (15.7) 
Kaplan-Meier 
analysis: 
20.5% (95% CI: 
11.5-28.6) vs. 
19.1% (95% CI: 
11.6-26.0) 
Single-/dual-chamber 
ICD HR with 
adjustment for ICD 
programming: 
0.85, p = 0.64 
NR NR NR Mean 2.6 years: 
Subcutaneous ICD: 
3/69 (4.3) vs. Single-/ 
dual-chamber ICD: 
6/69 (8.7), 
p =0.49 
6 months: 
Subcutanous ICD: 
1/91 (1.1) vs. 
Single-chamber 
ICD: 2/91 (2.2), 
p = NR 
Lead 
complications  
n (%) 
Mean 7.1. months:b 
Subcutaneous ICD: 
0/69 (0) vs.  
Single chamber 
ICD: 2/69 (2.9) 
p = NR 
5 years: 
Subcutaneous ICD: 
1/140 (0.7) vs. 
Single-/dual-
chamber ICD: 
17/140 (12.1) 
Kaplan-Meier 
analysis: 
0.8% (95% CI: 
0.0-2.2) vs. 
11.5% (95% CI:  
5.3-17.2), p = 0.03 
In-Hospital:c 
Subcutaneous ICD: 2/1920 
(0.1) vs. Single-chamber 
ICD: 4/1920 (0.2),  
P = NR 
Subcutaneous ICD: 
2/1920 (0.1) vs.  
Dual-chamber ICD:  
12/1920 (0.6), 
p = NR 
NR NR Mean 2.6 years:d 
Subcutaneous ICD: 
0/69 (0) vs. Single-
/dual-chamber ICD: 
6/69 (8.7), 
p = 0.028 
NR 
Infections  
n (%) 
Mean 7.1. months:e 
Subcutaneous ICD: 
1/69 (1.4) vs. 
Single-chamber 
ICD: 1/69 (1.4), 
p = NR 
5 years: 
Subcutaneous ICD: 
5/140 (3.6) vs. 
Single-/dual-
chamber ICD: 
4/140 (2.9) 
Kaplan-Meier 
analysis: 
4.1% (95% CI 0.5-
7.7) vs. 3.6% (95% 
CI: 0.0-7.1), p = 0.36 
In-Hospital: 
Subcutaneous ICD: 
1/1920 (0.05) vs. Single-
chamber ICD: 0/1920 (0), 
p = NR 
Subcutaneous ICD: 
1/1920 (0.05) vs.  
Dual-chamber ICD: 
2/1920 (0.1), p = NR 
NR NR Mean 2.6 years:f 
Subcutaneous ICD: 
1/69 (1.4) vs. 
Single-/dual-chamber 
ICD: 4/69 (5.8) 
p = 0.37 
6 months:g 
Subcutaneous ICD: 
3/91 (3.3) vs. single-
chamber ICD:  
1/91 (1.1), 
p = NR 
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Author, year Köbe, 2013 [6] Brouwer, 2016 [7] Friedmann, 2016 [10] Pedersen, 2016 [5] Köbe, 2017 [8] Honoarbakhsh, 2017 [9] Mithani, 2017 [4] 
Haematoma  
n (%) 
Mean 7.1. months:h 
Subcutaneous ICD: 
1/69 (1.4) vs. 
Single-chamber 
ICD: 0/69 (0) 
p = NR 
NR In-Hospital: 
Subcutaneous ICD: 
7/1920 (0.4) vs.  
Single-chamber ICD:  
1/1920 (0.05), p = 0.07 
Subcutaneous ICD: 
7/1920 (0.4) vs.  
Dual-Chamber ICD:  
2/1920 (0.1), p = 0.18 
NR NR NR 6 months:i 
Subcutaneous ICD: 
1/91 (1.1) vs.  
Single-chamber 
ICD: 0/91 (0),  
p = NR 
Pericardial 
tamponade  
n (%) 
NR NR In-Hospital: 
Subcutaneous ICD: 
0/1920 (0) vs. Single-
chamber ICD: 0/1920(0), 
p = NR 
Subcutaneous ICD: 
0/1920 (0) vs. Dual-
chamber ICD 5/1920 (0.3), 
p = NR 
NR NR <30 days: 
Subcutaneous ICD: 
0/60 (0) vs. 
Single-/dual-chamber 
ICD: 1/69 (1.4), p = 1.0 
NR 
Abbreviations: AHA = American Heart Association, ACC = American College of Cardiology, ATP = antitachycardia pacing, HR = Hazard ratio, ICD = implantable cardioverter-defibrillator, 
ESC = European Society of Cardiology, LVEF = Left ventricular ejection fraction, pts = Patients, NR = not reported, VF = ventricular fibrillation, VT = ventricular tachycardia, TV = transvenous, 
SC = single chamber, S-ICD = Subcutaneous ICD, PRAETORIAN = Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy) trial, 
QoL = Quality of life, CI = Confidence Interval, CRT = Cardiac Resynchronization Therapy, TV-ICD = Transvenous ICD, SF-12 = 12-Item Short Form Health Survey,  
Explanations: 
a Adjusted for confounders 
b Reported as lead revision  
c Reported as lead dislodgement 
d Reported as lead-related complications resulting in lead intervention 
e Reported as infection requiring revision 
f Reported as device infection 
g Reported as infection requiring explant 
h Reported as Haematoma requiring revision 
i Reported as Haematoma requiring intervention 
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Risk of bias tables and GRADE evidence profile 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement, a third researcher was involved to solve the differences.  
Table A-2:  Risk of bias – study level (observational studies) [11]* 
 Selection Comparability Outcome  
Study Author,  
Year 
Representative
ness of the 
exposed cohort 
Selection  
of the non 
exposed cohort 
Ascertain-
ment of 
exposure 
Demonstration that 
outcome of interest was not 
present at start of study 
Comparability of 
cohorts on the basis of 
the design or analysis 
Assessment 
of outcome 
Was follow-up 
long enough for 
outcomes to occur 
Adequacy 
of follow up 
of cohorts 
Overall 
Risk of Bias 
Köbe, 2013 [6] 1 1 1 1 0 1 1 0 High 
Brouwer, 2016, [7] 1 0 1 1 2 1 1 0 Medium 
Friedman, 2016, [10] 1 0 1 1 2 1 0 1 Medium  
Pedersen, 2016 [5] 1 0 0 1 2 0 1 1 Medium 
Mithani, 2017 [4] 1 1 1 1 0 1 1 1 High 
Honarbakhs, 2017 [9] 1 1 1 1 2 1 1 0 Medium 
Köbe, 2017 [8] 1 1 0 1 1 0 1 0 High 
* A study can be awarded a maximum of one point (= star) for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability  
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Table A-3: Risk of bias – study level (systematic review), see [12] 
AMSTAR-2 Basu-Ray, 2017 [3] 
Research question and inclusion criteria include the components of PICO Yes 
Explicit statement that the review methods were established prior to the conduct of the review No 
Explain their selection of the study designs for inclusion in the review Yes 
Comprehensive literature search strategy Yes 
Perform study selection in duplicate Yes 
Perform data extraction in duplicate Yes 
Provide a list of excluded studies and justify the exclusions No 
Describe the included studies in adequate detail Yes 
Satisfactory technique for assessing the risk of bias (RoB) in individual studies Yes 
Report on the sources of funding for the studies included in the review No 
Appropriate methods for statistical combination of results Yes 
Assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis No 
Account for RoB in individual studies when interpreting/discussing the results of the review No 
Satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review No 
Adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review?  Yes 
Report any potential sources of conflict of interest, including any funding they received for conducting the review?  Yes 
Rating for overall confidence in the results of the review Moderate* 
Moderate – More than one non-critical weakness*: The systematic review has more than one weakness, but no critical flaws.  
It may provide an accurate summary of the results of the available studies that were included in the review. [12]. 
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Table A-4: Evidence profile: comparative effectiveness and safety of the subcutaneous and transvenous ICD in patients at increased risk for sudden cardiac death  
Quality assessment № of patients Effect 
Certainty № of 
studies 
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Subcutaneous 
ICD 
Transvenous 
ICD 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Mortality (In-hospital) [10] 
1  observational 
studies 
not 
serious 
not serious not serious serious a none 3/1920 
(0.2%) 
3/3840 
(0.1%) 
RR 2.0 
(0.4 to 9.9) 
1 more per 1.000 
(from 0 fewer to 7 more) 
⨁◯◯◯ 
VERY LOW 
Mortality (up to 6 months) [4] 
1  observational 
studies 
serious b not serious not serious serious c,d none 2/91 (2.2%) 2/91 (2.2%) RR 1.00 
(0.14 to 6.95) 
0 fewer per 1.000 
(from 19 fewer to 131 more) 
⨁◯◯◯ 
VERY LOW 
Mortality (up to 5 years) [7] 
1  observational 
studies 
not 
serious 
not serious not serious serious c,d none 2/140 
(1.4%) 
6/140 (4.3%) -  ⨁◯◯◯ 
VERY LOW 
Appropriate shocks (7.1 months) [6] 
1  observational 
studies 
serious b not serious not serious serious c,d none 3/69 (4.3%) 9/69 (13.0%) RR 0.33 
(0.09 to 1.18) 
87 fewer per 1.000 
(from 23 more to 119 fewer) 
⨁◯◯◯ 
VERY LOW 
Appropriate shocks (2.6 years) [9] 
1  observational 
studies 
not 
serious 
not serious not serious serious c,d none 3/69 (4.3%) 5/69 (7.2%) RR 0.60 
(0.15 to 2.14) 
29 fewer per 1.000 
(from 62 fewer to 83 more) 
⨁◯◯◯ 
VERY LOW 
Appropriate shocks (up to 5 years) [7] 
1  observational 
studies 
not 
serious 
not serious not serious serious d none 12/140 
(8.6%) 
24/140 
(17.1%) 
HR 0.68 51 fewer per 1.000 
(from -- to --) 
⨁◯◯◯ 
VERY LOW 
Inappropriate shocks [3] pooled Data of [4, 6, 7, 9] 
4  observational 
studies 
serious b not serious not serious serious a none 29/369 
(7.9%) 
33/369 
(8.9%) 
OR 0.87 
(0.51 to 1.49) 
11 fewer per 1.000 
(from 40 more to 44 fewer) 
⨁◯◯◯ 
VERY LOW 
Lead complications [3] pooled Data of [6, 7, 9, 10] 
4  observational 
studies 
serious e not serious not serious not serious none 3/2198 
(0.1%) 
42/4118 
(1.0%) 
OR 0.13 
(0.05 to 0.38) 
9 fewer per 1.000 
(from 6 fewer to 10 fewer) 
⨁◯◯◯ 
VERY LOW 
Infections [3] pooled Data of [4, 6, 7, 9, 10] 
5  observational 
studies 
serious b not serious not serious not serious none 8/2289 
(0.3%) 
13/4209 
(0.3%) 
OR 0.75 
(0.30 to 1.89) 
1 fewer per 1.000 
(from 2 fewer to 3 more) 
⨁◯◯◯ 
VERY LOW 
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Quality assessment № of patients Effect 
Certainty № of 
studies 
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Subcutaneous 
ICD 
Transvenous 
ICD 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Pericardial tamponade [9, 10] 
2  observational 
studies 
not 
serious 
not serious not serious serious c none 0/1989 
(0.0%) 
6/3909 
(0.2%) 
RR ranged 
from  
0.18 to 0.33 
not estimable ⨁◯◯◯ 
VERY LOW 
Haematoma [4, 6, 10] 
3  observational 
studies 
serious b not serious not serious serious c none 9/2080 
(0.4%) 
3/4000 
(0.1%) 
RR ranged 
from  
3.0 to 3.5 
not estimable ⨁◯◯◯ 
VERY LOW 
Quality of life – physical well-being score [8] (assessed with: 12-item Short-Form Health Survey (SF-12)) 
1  observational 
studies 
serious b not serious not serious serious d none 42 42 - MD 6.7 higher 
(1.88 higher to 11.52 higher) 
⨁◯◯◯ 
VERY LOW 
Quality of life – physical well-being score [5] (assessed with: 12-item Short-Form Health Survey (SF-12)) 
1  observational 
studies 
not 
serious 
not serious not serious serious d none 167 167 - MD 0.2 lower 
(2.67 lower to 2.27 higher) 
⨁◯◯◯ 
VERY LOW 
Quality of life – mental well-being score [8] (assessed with: 12-item Short-Form Health Survey (SF-12)) 
1  observational 
studies 
serious b not serious not serious serious d none 42 42 - MD 0.1 higher 
(4.43 lower to 4.63 higher) 
⨁◯◯◯ 
VERY LOW 
Quality of life – mental well-being score [5] (assessed with: 12-item Short-Form Health Survey (SF-12)) 
1  observational 
studies 
not 
serious f 
not serious not serious serious d none 167 167 - MD 0.15 higher 
(2.44 lower to 2.74 higher) 
⨁◯◯◯ 
VERY LOW 
Abbreviations: CI = Confidence interval; RR = Risk ratio; HR = Hazard Ratio; OR = Odds ratio; MD = Mean difference 
Explanations: 
a Effect estimates includes appreciable benefit and harms  
b Two studies with high risk of bias [4, 6]  
c Small number of events  
d Sample size does not meet optimal information size.  
e Studies with high or medium risk of bias  
f Medium risk of bias  
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Applicability table 
Table A-5: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population Patients populations of included studies reflect real-world conditions with respect to age, sex, underlying cardiac condition and comorbidities.  
Intervention Included studies evaluated the subcutaneous ICD, produced by one manufacturer. 
Comparators Transvenous ICDs is considered as an established medical device, which is available from different manufacturers as single- or dual-chamber ICD. 
Outcomes Included studies reported several efficacy and safety outcomes, however, follow-up duration considerably differs among studies.  
Thus, long-term complications are only reflected by one study. 
Setting Studies were conducted in real-world settings.  
 
List of ongoing randomised controlled trials 
Table A-6: List of ongoing randomised controlled trials of subcutaneous ICD 
Identifier/ 
Trial name Patient population Intervention Comparison Primary Outcome 
Primary 
completion date 
Sponsor and 
Collaborator: 
NCT01296022 
PRAETORIAN 
Patients 18 years and older with class I or IIa indication 
for ICD therapy according to the ACC/AHA/ESC 2006 
Guidelines for Management of Patients With Ventricular 
Arrhythmias and the Prevention of Sudden Cardiac Death 
Estimated enrollment: 850 patients 
Subcutaneous 
ICD 
Transvenous 
ICD 
Number of participants 
with implantable 
cardioverter defibrillator 
(ICD) related adverse 
events (48 months) 
Estimated: 
December 2019 
Academisch Medisch 
Centrum-Universiteit 
van Amsterdam  
(AMC-UvA) 
Boston Scientific 
Corporation 
NCT02881255 
ATLAS S-ICD 
Patient is ≥ 18-60 years old AND has a standard indication 
for ICD; OR Patient is ≥ 18 years old AND has any one of 
the following present: An inherited arrhythmia syndrome 
(i.e. Long QT, Brugada, ARVC, hypertrophic or dilated 
cardiomyopathy, early repolarization syndrome, idiopathic 
ventricular fibrillation, etc.), prior pacemaker or ICD 
removal for infection, need for hemodialysis, prior heart 
valve surgery (repair or replacement), Chronic obstructive 
pulmonary disease (with FEV1 < 1.5 L) 
Estimated enrollment: 500 patients 
Subcutaneous 
ICD (Boston 
Scientific 
EMBLEM™) 
Single-
chamber, 
transvenous 
ICD 
Composite of lead-related 
perioperative complications 
(6 months) 
Additional safety composite 
(6 months) 
Estimated: 
August 2018 
Population Health 
Research Institute 
Boston Scientific 
Corporation 
Abbreviations: ATALS = Avoid Transvenous Leads in Appropriate Subjects, PRAETORIAN = Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable 
cardioverter-defibrillator therapy, ICD = Impantable cardioverter defibrillator 
Appendix 
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Literature search strategies 
Search strategy for Pubmed 
Search Name: Subcutaneous ICD 
Search Date: November 23rd, 2017 
ID Search 
#1 Search S-ICD[tw] 
#2 Search subcutaneous*[tw] 
#3 Search "Defibrillators, Implantable"[Mesh] 
#4 Search cardioverter*[tiab] 
#5 Search defibrillator*[tiab] 
#6 Search ICD[tiab] 
#7 Search (#3 OR #4 OR #5 OR #6) 
#8 Search (#2 AND #7) 
#9 Search (#1 OR #8) 
#10 Search "Animals"[Mesh] NOT "Humans"[Mesh] 
#11 Search #9 NOT #10 
#12 Search (#11) AND ("2000"[Date - Publication] : "3000"[Date - Publication]) 
#13 Search "Case Reports" [Publication Type] OR (case*[ti] AND (report*[ti] OR series[ti])) 
#14 Search (#12 NOT #13) 
Total: 410 Hits 
 
 
Search strategy for Embase.com (Elsevier) 
Search Name: Subcutaneous ICD 
Search Date: November 23rd, 2017 
ID Search 
#1 's icd':ti,ab 
#2 (subcutaneous* NEAR/4 (defibrillator* OR cardioverter* OR icd)):ti,ab 
#3 'implantable cardioverter defibrillator'/exp AND subcutaneous* 
#4 #1 OR #2 OR #3 
#5 'animal'/exp NOT 'human'/exp 
#6 #4 NOT #5 
#7 #6 AND [2000-2017]/py 
#8 'case study'/exp OR 'case report'/exp OR ((case* NEAR/3 (report OR series)):ti) 
#9 #7 NOT #8 
#10 #9 NOT 'conference abstract'/it 
Total: 341 Hits 
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Search strategy for Cochrane Library (Wiley) 
Search Name: Subcutaneous ICD 
Search Date: November 23rd, 2017 
ID Search 
#1 S-ICD:ti,ab,kw  
#2 subcutaneous* near/4 (defibrillator* or Cardioverter* or ICD)  
#3 subcutaneous*:ti,ab,kw  
#4 [mh "Defibrillators, Implantable"]  
#5 cardioverter*:ti,ab,kw  
#6 defibrillator*:ti,ab,kw  
#7 ICD:ti,ab,kw  
#8 {or, #4-`#7}  
#9 #3 and #8  
#10 #1 or #2 or #9  
#11 #10 Publication Year from 2000 to 2017 
Total: 79 Hits 
 
 
Search strategy for CRD Databases 
Search Name: Subcutaneous ICD 
Search Date: November 23rd, 2017 
ID Search 
#1 MeSH DESCRIPTOR Defibrillators, Implantable EXPLODE ALL TREES 
#2 (Subcutaneous*) 
#3 #1 AND #2 
#4 (S-ICD) 
#5 (subcutaneous* NEAR4 (defibrillator* OR Cardioverter* OR ICD) ) 
#6 #3 OR #4 OR #5 
Total: 5 Hits 
 
 
 

  
 
